
                                SEQUENCE LISTING

<110> Merck Sharp & Dohme Corp.
      Luo, Peter Peizhi
      Wang, Kevin Caili
      Zhong, Pingyu
      Hsieh, Mark
      Li, Yan
      Wang, Xinwei
      Dong, Feng
      Golosov, Andrei
      Ni, Yan
      Wang, Weirong
      Peterson, Laurence B.
      Cubbon, Rose
      Sharma, Sujata
      Condra, Jon
      Lu, Jun
      Parthasarathy, Gopalakrishnan
      Soisson, Stephen
      Byrne, Noel

<120> AX213 AND AX132 PCSK9 ANTAGONISTS
  

<130> MRL-ACV-00029

<150> US 61/323,148       
<151> 2010-04-12  

<150> US 61/256,732       
<151> 2009-10-30  

<160> 647

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> consensus sequence for AX213 and AX132 Heavy Chain
      CDR3 Antibody Region

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = A or S

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = E, Y, A, G, S. H, Q or D

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = R, K, F, N, H, D, S or Y

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = Y, V, S. D, I, L. F or A

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = G, Y or A

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = Y or W

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = Y, S, N or D

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = F or L

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = Y, N or F

<221> VARIANT        
<222> (15)...(15)
<223> Xaa = Q or E

<400> 1
Cys Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Trp Gly Xaa
 1               5                  10                  15  


<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      shorter CDR3 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = E, Y, A, G, S, H, Q or D

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = R, K, F, N, H, D, S or Y

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = Y, V, S, D, I, L, F or A

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = G, Y or A

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Y or W

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = Y, S, N or D

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = F or L

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = Y, N or F

<400> 2
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa
 1               5                  


<210> 3
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      CDR3 Antibody Region

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = E, Y, A, G, S, H, Q or D

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = R, K, F, N, H, D, S or Y

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = Y, V, S, D, I, L, F or A

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = G, Y or A

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = Y, S, N or D

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = F or L

<221> VARIANT        
<222> (15)...(15)
<223> Xaa = Q or E

<400> 3
Cys Ala Arg Xaa Xaa Xaa Xaa Tyr Xaa Xaa Asp Tyr Trp Gly Xaa
 1               5                  10                  15  


<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      shorter CDR3 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = E, Y, A, G, S, H, Q or D

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = R, K, F, N, H, D, S or Y

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = Y, V, S, D, I, L, F or A

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = G, Y or A

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = Y, S, N or D

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = F or L

<400> 4
Xaa Xaa Xaa Xaa Tyr Xaa Xaa Asp Tyr
 1               5                  


<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain CDR3 Antibody Region

<400> 5
Cys Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 6
<211> 45
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain CDR3 Antibody Region

<400> 6
tgcgcccgtg aacgttacgg ttactacttc gactactggg gtcag                 45

<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain shorter CDR3 Antibody Region

<400> 7
Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr
 1               5                  


<210> 8
<211> 27
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain shorter CDR3 Antibody Region

<400> 8
gaacgttacg gttactactt cgactac                                     27

<210> 9
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain CDR3 Antibody Region

<400> 9
Cys Ala Arg Ala Asn Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 10
<211> 45
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain CDR3 Antibody Region

<400> 10
tgcgcccgtg caaatgacgg ttactccttc gactactggg gtcag                 45

<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain shorter CDR3 Antibody Region

<400> 11
Ala Asn Asp Gly Tyr Ser Phe Asp Tyr
 1               5                  


<210> 12
<211> 27
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain shorter CDR3 Antibody Region

<400> 12
gcaaatgacg gttactcctt cgactac                                     27

<210> 13
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 13
Cys Ala Arg Ala Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 14
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 14
Cys Ala Arg Tyr Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 15
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 15
Cys Ala Arg Gln Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 16
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 16
Cys Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 17
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 17
Cys Ala Arg Ser Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 18
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 18
Cys Ala Arg Tyr Arg Ser Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 19
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 19
Cys Ala Arg Glu Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 20
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 20
Cys Ala Arg His Arg Val Gly Tyr Ser Leu Asp Phe Trp Gly Gln
 1               5                  10                  15  


<210> 21
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 21
Cys Ala Arg Tyr His Tyr Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 22
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 22
Cys Ala Arg Tyr His Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 23
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 23
Cys Ala Arg Glu Arg Phe Ala Tyr Tyr Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 24
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 24
Cys Ala Arg Ser Arg Asp Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 25
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 25
Cys Ala Arg Ala Arg Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 26
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 26
Cys Ala Arg Glu Arg Ala Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 27
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 27
Cys Ala Arg His Arg Val Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 28
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 28
Cys Ala Arg Ala Asn Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 29
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 29
Cys Ala Arg Ser His Val Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 30
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 30
Cys Ala Arg His Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 31
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 31
Cys Ala Arg Ser Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 32
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 32
Cys Ala Arg Tyr Arg Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 33
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 33
Cys Ala Arg Asp Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 34
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 34
Cys Ala Arg Gln Arg Val Gly Tyr Asn Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 35
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 35
Cys Ala Arg Gln Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Glu
 1               5                  10                  15  


<210> 36
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 36
Cys Ala Arg Ser Arg Asp Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 37
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 37
Cys Ala Arg Tyr Arg Ser Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 38
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 38
Cys Ala Arg Tyr Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 39
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 39
Cys Ala Arg Ser Arg Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 40
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 40
Cys Ala Arg Ala Arg Asp Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 41
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 41
Cys Ala Arg His Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 42
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 42
Cys Ala Arg Ala Asp Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 43
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 43
Cys Ala Arg Gly Phe Val Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 44
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 44
Cys Ala Arg Gly Phe Ile Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 45
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 45
Cys Ala Arg Gly Phe Leu Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 46
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 46
Cys Ala Arg Gly Arg Ile Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 47
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 47
Cys Ala Arg Gly Arg Phe Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 48
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 48
Cys Ala Arg Gly Arg Leu Tyr Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 49
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 49
Cys Ala Arg Gly Phe Ile Tyr Tyr Asp Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 50
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 50
Cys Ala Arg Gly Lys Ile Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 51
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 51
Cys Ala Arg Gly Tyr Leu Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 52
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 52
Cys Ala Arg Gly Phe Ile Tyr Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 53
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 53
Cys Ala Arg Gly Asn Leu Tyr Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 54
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 54
Cys Ser Arg Gly Lys Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 55
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 55
Cys Ala Arg Gly Ser Ile Gly Tyr Asn Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 56
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 56
Cys Ala Arg Gly Arg Asp Gly Tyr Ser Leu Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 57
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 57
Cys Ala Arg Glu Lys Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 58
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 58
Cys Ala Arg Tyr Lys Ser Gly Trp Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 59
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 59
Cys Ala Arg Tyr Arg Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 60
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 60
Cys Ala Arg Tyr Lys Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 61
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 61
Cys Ala Arg Glu Lys Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 62
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 62
Cys Ala Arg Glu Arg Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln
 1               5                  10                  15  


<210> 63
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR3 Antibody Region

<400> 63
Cys Ala Arg Ser Arg Val Gly Tyr Ser Phe Asp Asn Trp Gly Gln
 1               5                  10                  15  


<210> 64
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      CDR2 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = W, S or Q

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = I or V

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = W, R, Y, S, L or Q

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = I or D

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = D, N, R, Q or S

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = G, R, S, K, N or D

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = S, N, Q, G or Y

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = G or R

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = G, W, S or T

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = T, H, P or S

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = K, R, N, Q, S or Y

<221> VARIANT        
<222> (14)...(14)
<223> Xaa = Y, V, Q or L

<221> VARIANT        
<222> (15)...(15)
<223> Xaa = N, Q, A, E, D, Y, S or T

<221> VARIANT        
<222> (16)...(16)
<223> Xaa = E, Q, D, P, R or H

<221> VARIANT        
<222> (17)...(17)
<223> Xaa = K, Q or S

<221> VARIANT        
<222> (18)...(18)
<223> Xaa = F or V

<221> VARIANT        
<222> (19)...(22)
<223> Xaa = at position 19 K, Q or E; at position 20 ,
      S, or D; at postion 21 K, R or Q; at position 22
      A, V, F or T

<400> 64
Xaa Xaa Gly Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1               5                  10                  15      
Xaa Xaa Xaa Xaa Xaa Xaa Thr
            20              


<210> 65
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      Shorter CDR2 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa =  R, Y, S, L or Q

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = I or D

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = D, N, R, Q or S

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = G, R, S, K, N or D

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S, N, Q, G or Y

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = G or R

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = G, W, S or T

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = T, H, P or S

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = K, R, N, Q, S or Y

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = Y, V, Q or L

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = N, Q, A, E, D, Y, S or T

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = E, Q, D, P, R or H

<221> VARIANT        
<222> (14)...(14)
<223> Xaa = K, Q or S

<221> VARIANT        
<222> (15)...(15)
<223> Xaa = F or V

<221> VARIANT        
<222> (16)...(16)
<223> Xaa = K, Q or E

<221> VARIANT        
<222> (17)...(17)
<223> Xaa = G, S or D

<400> 65
Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1               5                  10                  15      
Xaa
    


<210> 66
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      CDR2 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = W, S or Q

<221> VARIANT        
<222> (2)...(2)
<223> XAA at position 2 = I or V

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = W, R, Y, S, L or Q

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = I or D

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = D, N, R, Q or S

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = G, R, S, K, N or D

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = S, N, Q, G or Y

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = G or R

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = G, W, S or T

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = T, H, P or S

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = K, R, N, Q, S or Y

<221> VARIANT        
<222> (15)...(15)
<223> Xaa = N, Q, A, E, D, Y, S or T

<221> VARIANT        
<222> (16)...(16)
<223> Xaa = E, Q, D, P, R or H

<221> VARIANT        
<222> (17)...(17)
<223> Xaa = K, Q or S

<221> VARIANT        
<222> (18)...(18)
<223> Xaa = F or V

<221> VARIANT        
<222> (19)...(19)
<223> Xaa = K, Q or E

<221> VARIANT        
<222> (20)...(22)
<223> Xaa = at position 20 G, S or D; at position 21 K,
      R or Q; Xaa at position 22 A, V, F or T

<400> 66
Xaa Xaa Gly Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa
 1               5                  10                  15      
Xaa Xaa Xaa Xaa Xaa Xaa Thr
            20              


<210> 67
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      shorter CDR2 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = W, R, Y, S, L or Q

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = I or D

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = D, N, R, Q or S

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = G, R, S, K, N or D

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S, N, Q, G or Y

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = G or R

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = G, W, S or T

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = T, H, P or S

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = K, R, N, Q, S or Y

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = N, Q, A, E, D, Y, S or T

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = E, Q, D, P, R or H

<221> VARIANT        
<222> (14)...(14)
<223> Xaa = K, Q or S

<221> VARIANT        
<222> (15)...(15)
<223> Xaa = F or V

<221> VARIANT        
<222> (16)...(16)
<223> Xaa = K, Q or E

<221> VARIANT        
<222> (17)...(17)
<223> Xaa = G, S or D

<400> 67
Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa
 1               5                  10                  15      
Xaa
    


<210> 68
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain CDR2 Antibody Region

<400> 68
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 69
<211> 69
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain CDR2 Antibody Region

<400> 69
tggatcggtt ggatcgaccc aggcagcggt ggcaccaagt acaacgaaaa gttcaagggt 60
aaggccacc                                                         69

<210> 70
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain shorter CDR2 Antibody Region

<400> 70
Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 71
<211> 51
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain shorter CDR2 Antibody Region

<400> 71
tggatcgacc caggcagcgg tggcaccaag tacaacgaaa agttcaaggg t          51

<210> 72
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain CDR2 Antibody Region

<400> 72
Trp Ile Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 73
<211> 69
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain CDR2 Antibody Region

<400> 73
tggatcggtc ggatcgaccc aggtaacggt ggtactaggt acaacgaaaa gttcaagggt 60
aaggccacc                                                         69

<210> 74
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain shorter CDR2 Antibody Region

<400> 74
Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 75
<211> 51
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain shorter CDR2 Antibody Region

<400> 75
cggatcgacc caggtaacgg tggtactagg tacaacgaaa agttcaaggg t          51

<210> 76
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 76
Trp Ile Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 77
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 77
Trp Ile Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 78
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 78
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 79
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 79
Gln Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Ser Lys Ala Thr
            20              


<210> 80
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 80
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 81
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 81
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 82
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 82
Trp Ile Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Ser Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Ser Lys Ala Thr
            20              


<210> 83
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 83
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 84
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 84
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Gln Ala Thr
            20              


<210> 85
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 85
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 86
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 86
Trp Ile Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Ser Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 87
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 87
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Gln Phe Gln Gly Lys Ala Thr
            20              


<210> 88
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 88
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 89
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 89
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 90
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 90
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 91
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 91
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 92
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 92
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 93
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 93
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Ser Lys Ala Thr
            20              


<210> 94
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 94
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Ser Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 95
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 95
Trp Ile Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 96
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 96
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 97
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 97
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Ser Lys Ala Thr
            20              


<210> 98
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 98
Trp Ile Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Gln Phe Lys Gly Lys Ala Thr
            20              


<210> 99
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 99
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Glu Gly Lys Ala Thr
            20              


<210> 100
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 100
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 101
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 101
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 102
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 102
Trp Ile Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Gln Phe Lys Gly Lys Ala Thr
            20              


<210> 103
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 103
Trp Ile Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Gln Phe Gln Gly Lys Ala Thr
            20              


<210> 104
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 104
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 105
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 105
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 106
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 106
Trp Ile Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Asn Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 107
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 107
Trp Ile Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Gln Phe Gln Gly Lys Ala Thr
            20              


<210> 108
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 108
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 109
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 109
Trp Ile Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 110
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 110
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Ser Lys Ala Thr
            20              


<210> 111
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 111
Trp Ile Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 112
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 112
Trp Ile Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 113
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 113
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 114
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 114
Trp Ile Gly Arg Ile Asp Pro Ser Asn Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 115
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 115
Trp Ile Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 116
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 116
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 117
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 117
Trp Val Gly Arg Ile Ser Pro Ser Gly Gly Ser Thr Tyr Tyr Ala Asp
 1               5                  10                  15      
Ser Val Lys Gly Arg Phe Thr
            20              


<210> 118
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 118
Trp Ile Gly Arg Ile Asn Pro Gly Ser Gly Gly Thr Lys Tyr Asp Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 119
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 119
Trp Ile Gly Trp Ile Asn Pro Asp Ser Gly Ser Thr Lys Tyr Ala Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 120
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 120
Trp Ile Gly Arg Ile Asp Pro Ser Ser Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 121
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 121
Trp Val Gly Arg Ile Ser Pro Gly Gly Gly Thr Thr Tyr Tyr Ala Asp
 1               5                  10                  15      
Ser Val Lys Gly Arg Phe Thr
            20              


<210> 122
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 122
Trp Ile Gly Arg Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asp Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 123
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 123
Trp Ile Gly Arg Ile Asn Pro Lys Gln Arg Trp His Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Val Thr
            20              


<210> 124
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 124
Trp Ile Gly Leu Asp Arg Pro Arg Gln Arg Trp His Gln Leu Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 125
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 125
Ser Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 126
<211> 24
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 126
Trp Ile Gly Leu Asp Arg Pro Lys Gln Arg Val Gly Thr Lys Tyr Asn
 1               5                  10                  15      
Gln Lys Phe Gln Gly Arg Val Thr
            20                  


<210> 127
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 127
Trp Ile Gly Leu Asp Arg Pro Arg Gln Arg Trp Pro Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 128
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 128
Trp Ile Gly Leu Asp Arg Pro Lys Gln Arg Trp His Gln Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 129
<211> 24
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 129
Trp Ile Gly Ser Asp Arg Pro Arg Gln Arg Val Ala Pro Lys Tyr Asn
 1               5                  10                  15      
Gln Lys Phe Lys Gly Arg Ala Thr
            20                  


<210> 130
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 130
Trp Ile Gly Arg Ile Asp Pro Ser Ser Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Gly Arg Val Thr
            20              


<210> 131
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 131
Trp Ile Gly Leu Asp Arg Pro Lys Gln Arg Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 132
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 132
Trp Ile Gly Ser Asp Arg Pro Arg Gln Arg Trp His Gln Val Gln Arg
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 133
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 133
Trp Ile Gly Arg Ile Asp Pro Asn Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 134
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 134
Trp Ile Gly Arg Ile Asn Pro Ser Ser Gly Gly Thr Asn Tyr Asn Glu
 1               5                  10                  15      
Gln Phe Gln Gly Arg Ala Thr
            20              


<210> 135
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 135
Trp Ile Gly Ser Asp Arg Pro Arg Gln Arg Trp His Gln Val Gln Pro
 1               5                  10                  15      
Lys Val Gln Gly Arg Ala Thr
            20              


<210> 136
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 136
Trp Ile Gly Arg Ile Asp Pro Asn Ser Gly Gly Thr Lys Gln Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 137
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 137
Ser Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 138
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 138
Trp Ile Gly Leu Asp Arg Pro Arg Gln Arg Trp His Gln Val Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 139
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 139
Trp Ile Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Val Thr
            20              


<210> 140
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 140
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Val Thr
            20              


<210> 141
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 141
Trp Ile Gly Gln Asp Arg Pro Lys Tyr Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Val Thr
            20              


<210> 142
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 142
Trp Ile Gly Arg Ile Asn Pro Ser Asn Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 143
<211> 24
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 143
Trp Ile Gly Ser Asp Arg Pro Arg Gln Arg Trp Gly Thr Lys Tyr Asn
 1               5                  10                  15      
Glu Lys Phe Gln Gly Arg Val Thr
            20                  


<210> 144
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 144
Trp Ile Gly Trp Ile Asn Pro Ser Asn Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 145
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 145
Trp Ile Gly Ser Asp Gln Pro Arg Gln Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 146
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 146
Trp Ile Gly Ser Asp Arg Pro Arg Gln Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Asp Arg Val Thr
            20              


<210> 147
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 147
Trp Ile Gly Ser Asp Arg Pro Lys Gln Arg Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Val Thr
            20              


<210> 148
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 148
Ser Ile Gly Arg Ile Asn Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 149
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 149
Trp Ile Gly Ser Asp Arg Pro Lys Gln Arg Trp His Gln Val Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Val Thr
            20              


<210> 150
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 150
Trp Ile Gly Arg Ile Asp Pro Asp Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 151
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 151
Trp Ile Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 152
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 152
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 153
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 153
Trp Ile Gly Arg Ile Asn Pro Asp Asn Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Val Thr
            20              


<210> 154
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 154
Trp Ile Gly Arg Asp Gln Pro Arg Gln Gly Gly Thr Asn Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Ala Thr
            20              


<210> 155
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 155
Trp Ile Gly Arg Ile Asn Pro Asn Asn Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 156
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 156
Trp Ile Gly Ser Asp Arg Pro Arg Gln Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Val Thr
            20              


<210> 157
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 157
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Arg Val Thr
            20              


<210> 158
<211> 24
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 158
Trp Ile Gly Ser Asp Arg Pro Lys Gln Arg Trp Ala Pro Lys Tyr Asn
 1               5                  10                  15      
Glu Lys Phe Lys Gly Arg Ala Thr
            20                  


<210> 159
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 159
Trp Ile Gly Ser Asp Gln Pro Arg Gln Arg Trp His Gln Val Gln Pro
 1               5                  10                  15      
Lys Val Gln Gly Arg Val Thr
            20              


<210> 160
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 160
Trp Ile Gly Arg Ile Asn Pro Gly Asn Gly Gly Thr Lys Gln Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 161
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 161
Trp Ile Gly Arg Ile Asn Pro Ser Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Ala Thr
            20              


<210> 162
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 162
Trp Ile Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Arg Val Thr
            20              


<210> 163
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 163
Trp Ile Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Arg Thr Thr
            20              


<210> 164
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 164
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Asp
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 165
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 165
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Val Thr
            20              


<210> 166
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 166
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 167
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 167
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Asn Tyr Gln Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 168
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 168
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Asn Tyr Gln Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 169
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 169
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Ala Asp
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 170
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 170
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Glu Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 171
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 171
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Asp
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 172
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 172
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Tyr Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 173
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 173
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Glu Asp
 1               5                  10                  15      
Lys Phe Glu Gly Lys Ala Thr
            20              


<210> 174
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 174
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Asn Tyr Thr Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 175
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 175
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Ser His
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 176
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 176
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 177
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 177
Trp Ile Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Ser Lys Ala Thr
            20              


<210> 178
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 178
Trp Ile Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Ser Lys Ala Thr
            20              


<210> 179
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 179
Trp Ile Gly Trp Ile Asp Pro Gly Asn Gly Gly Ser Arg Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 180
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 180
Trp Ile Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 181
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 181
Trp Ile Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Lys Tyr Asn Gln
 1               5                  10                  15      
Lys Phe Gln Gly Lys Ala Thr
            20              


<210> 182
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR2 Antibody Region

<400> 182
Trp Ile Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu
 1               5                  10                  15      
Lys Phe Lys Gly Lys Ala Thr
            20              


<210> 183
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      CDR1 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = K, A, E, Q or T

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = A or T

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = G or D

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Y, F, L or Q

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = T or S

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = F or Y

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = S or T

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = S, R, A, N, D, T or Y

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Y, F or Q

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = G, S, T, A, Y, Q or W

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = M, I, F, Y, N or Q

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = Y, S, N, T, H or I

<221> VARIANT        
<222> (15)...(15)
<223> Xaa = V or M

<400> 183
Xaa Xaa Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Trp Xaa Arg
 1               5                  10                  15      


<210> 184
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      shorter CDR1 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = G or D

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Y, F, L or Q

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = T or S

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = F or Y

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = S or T

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S, R, A, N, D, T or Y

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = Y, F or Q

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = G, S, T, A, Y, Q or W

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = M, I, F, Y, N or Q

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Y, S, N, T, H or I

<400> 184
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1               5                  10  


<210> 185
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      CDR1 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = K, A, E, Q or T

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = G or D

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Y, F, L or Q

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = T or S

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = S or T

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = S, R, A, N, D, T or Y

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Y, F or Q

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = G, S, T, A, Y, Q or W

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = M, I, F, Y, N or Q

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = Y, S, N, T, H or I

<221> VARIANT        
<222> (15)...(15)
<223> Xaa = V or M

<400> 185
Xaa Ala Ser Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Trp Xaa Arg
 1               5                  10                  15      


<210> 186
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      shorter CDR1 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = G or D

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Y, F, L or Q

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = T or S

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = S or T

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S, R, A, N, D, T or Y

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = Y, F or Q

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = G, S, T, A, Y, Q or W

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = M, I, F, Y, N or Q

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Y, S, N, T, H or I

<400> 186
Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa
 1               5                  10  


<210> 187
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      CDR1 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = K, A, E, Q or T

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = G or D

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Y, F, L or Q

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = T or S

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = S or T

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = S, R, A, N, D, T or Y

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Y, F or Q

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = G, S, T, A, Y, Q or W

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = M, I, F, Y, N or Q

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = Y, S, N, T, H or I

<400> 187
Xaa Ala Ser Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Trp Val Arg
 1               5                  10                  15      


<210> 188
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Heavy Chain
      shorter CDR1 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = G or D

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Y, F, L or Q

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = T or S

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = S or T

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S, R, A, N, D, T or Y

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = Y, F or Q

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = G, S, T, A, Y, Q or W

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = M, I, F, Y, N or Q

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Y, S, N, T, H or I

<400> 188
Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa
 1               5                  10  


<210> 189
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain CDR1 Antibody Region

<400> 189
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 190
<211> 48
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain CDR1 Antibody Region

<400> 190
aaggcctctg gttacacctt ctcttcttac gggatgtact gggtgcgt              48

<210> 191
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain shorter CDR1 Antibody Region

<400> 191
Gly Tyr Thr Phe Ser Ser Tyr Gly Met Tyr
 1               5                  10  


<210> 192
<211> 30
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 Heavy Chain shorter CDR1 Antibody Region

<400> 192
ggttacacct tctcttctta cgggatgtac                                  30

<210> 193
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain CDR1 Antibody Region

<400> 193
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Gly Ile Asn Trp Val Arg
 1               5                  10                  15      


<210> 194
<211> 48
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain CDR1 Antibody Region

<400> 194
aaggctagcg gttacacctt ctctcgctac ggtatcaact gggtgcgt              48

<210> 195
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain shorter CDR1 Antibody Region

<400> 195
Gly Tyr Thr Phe Ser Arg Tyr Gly Ile Asn
 1               5                  10  


<210> 196
<211> 30
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 Heavy Chain shorter CDR1 Antibody Region

<400> 196
ggttacacct tctctcgcta cggtatcaac                                  30

<210> 197
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 197
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Ser Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 198
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 198
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Gln Gly Phe Thr Trp Val Arg
 1               5                  10                  15      


<210> 199
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 199
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Ser Phe Ser Trp Val Arg
 1               5                  10                  15      


<210> 200
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 200
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Gly Ile Ser Trp Val Arg
 1               5                  10                  15      


<210> 201
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 201
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Thr Asn Tyr Trp Val Arg
 1               5                  10                  15      


<210> 202
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 202
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ser Tyr Tyr Trp Val Arg
 1               5                  10                  15      


<210> 203
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 203
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Ala Asn Thr Trp Val Arg
 1               5                  10                  15      


<210> 204
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 204
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Tyr Tyr Trp Val Arg
 1               5                  10                  15      


<210> 205
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 205
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ala Ile Asn Trp Val Arg
 1               5                  10                  15      


<210> 206
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 206
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 207
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 207
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Gly Tyr Tyr Trp Val Arg
 1               5                  10                  15      


<210> 208
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 208
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ala Tyr Asn Trp Val Arg
 1               5                  10                  15      


<210> 209
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 209
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Gly Phe Ser Trp Val Arg
 1               5                  10                  15      


<210> 210
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 210
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ala Phe Asn Trp Val Arg
 1               5                  10                  15      


<210> 211
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 211
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 212
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 212
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Thr Ile Thr Trp Val Arg
 1               5                  10                  15      


<210> 213
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 213
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ser Phe Ile Trp Val Arg
 1               5                  10                  15      


<210> 214
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 214
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Thr Phe Tyr Trp Val Arg
 1               5                  10                  15      


<210> 215
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 215
Lys Ala Ser Gly Gln Thr Phe Ser Ser Tyr Gly Phe Asn Trp Val Arg
 1               5                  10                  15      


<210> 216
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 216
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ala Asn Tyr Trp Val Arg
 1               5                  10                  15      


<210> 217
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 217
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ser Asn Ser Trp Val Arg
 1               5                  10                  15      


<210> 218
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 218
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Ser Ile Thr Trp Val Arg
 1               5                  10                  15      


<210> 219
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 219
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Thr Tyr Thr Trp Val Arg
 1               5                  10                  15      


<210> 220
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 220
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Ser Tyr Tyr Trp Val Arg
 1               5                  10                  15      


<210> 221
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 221
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Tyr Ser Trp Val Arg
 1               5                  10                  15      


<210> 222
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 222
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Thr Phe Ser Trp Val Arg
 1               5                  10                  15      


<210> 223
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 223
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Phe Ser Trp Val Arg
 1               5                  10                  15      


<210> 224
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 224
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Gln Ser Trp Val Arg
 1               5                  10                  15      


<210> 225
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 225
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg
 1               5                  10                  15      


<210> 226
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 226
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Thr Tyr Asn Trp Val Arg
 1               5                  10                  15      


<210> 227
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 227
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg
 1               5                  10                  15      


<210> 228
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 228
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Thr Phe Asn Trp Val Arg
 1               5                  10                  15      


<210> 229
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 229
Lys Gly Gln Arg Leu Pro Pro Arg Tyr Gly Tyr Tyr Trp Val Arg
 1               5                  10                  15  


<210> 230
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 230
Lys Ala Ser Gly Tyr Thr Tyr Ser Arg Tyr Thr Phe Ser Trp Val Arg
 1               5                  10                  15      


<210> 231
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 231
Lys Ala Ser Asp Tyr Thr Phe Ser Ser Tyr Gly Asn Asn Trp Val Arg
 1               5                  10                  15      


<210> 232
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 232
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Ile Ser Trp Val Arg
 1               5                  10                  15      


<210> 233
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 233
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Thr Ile Asn Trp Val Arg
 1               5                  10                  15      


<210> 234
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 234
Lys Ala Ser Gly Phe Thr Phe Ser Ala Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 235
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 235
Lys Ala Ser Gly Phe Thr Phe Ser Asp Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 236
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 236
Lys Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gln Met Ser Trp Val Arg
 1               5                  10                  15      


<210> 237
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 237
Lys Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Tyr Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 238
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 238
Lys Ala Ser Gly Phe Thr Phe Thr Ala Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 239
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 239
Lys Ala Ser Gly Phe Thr Phe Thr Ser Tyr Gln Met Ser Trp Val Arg
 1               5                  10                  15      


<210> 240
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 240
Lys Ala Ser Gly Phe Thr Phe Thr Ser Tyr Trp Met Ser Trp Val Arg
 1               5                  10                  15      


<210> 241
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 241
Lys Ala Ser Gly Leu Thr Phe Thr Asp Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 242
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 242
Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 243
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 243
Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 244
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 244
Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn Trp Val Arg
 1               5                  10                  15      


<210> 245
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 245
Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 246
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 246
Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Ser Trp Val Arg
 1               5                  10                  15      


<210> 247
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 247
Gln Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 248
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 248
Glu Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 249
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 249
Glu Ala Ser Gly Phe Ser Phe Ser Asn Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 250
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 250
Ala Ala Ser Gly Tyr Ser Phe Ser Ala Tyr Tyr Ile His Trp Val Arg
 1               5                  10                  15      


<210> 251
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 251
Lys Ala Ser Gly Phe Ser Phe Ser Ser Tyr Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 252
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 252
Ala Ala Ser Gly Tyr Ser Phe Ser Thr Phe Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 253
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 253
Glu Ala Ser Gly Phe Thr Phe Ser Asp Tyr Gly Ile His Trp Val Arg
 1               5                  10                  15      


<210> 254
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 254
Ala Ala Ser Gly Tyr Thr Phe Ser Asp Phe Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 255
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 255
Gln Ala Ser Gly Tyr Ser Phe Thr Thr Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 256
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 256
Ala Ala Ser Gly Phe Thr Phe Thr Asn Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 257
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 257
Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Phe Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 258
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 258
Thr Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 259
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 259
Thr Ala Ser Gly Tyr Ser Phe Thr Ala Phe Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 260
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 260
Lys Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 261
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 261
Lys Ala Ser Gly Tyr Ser Phe Ser Ala Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 262
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 262
Glu Ala Ser Gly Tyr Thr Phe Thr Ser Phe Gln Met His Trp Val Arg
 1               5                  10                  15      


<210> 263
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 263
Ala Ala Ser Gly Tyr Thr Phe Ser Ser Phe Ser Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 264
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 264
Gln Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 265
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 265
Gln Ala Ser Gly Tyr Thr Phe Thr Ala Phe Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 266
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 266
Lys Ala Ser Gly Phe Ser Phe Thr Ser Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 267
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 267
Gln Ala Ser Gly Phe Thr Phe Ser Thr Tyr Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 268
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 268
Lys Ala Ser Gly Phe Ser Phe Ser Ser Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 269
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 269
Glu Ala Ser Gly Tyr Ser Phe Ser Asn Phe Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 270
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 270
Thr Ala Ser Asp Phe Ser Phe Ser Thr Phe Ser Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 271
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 271
Ala Ala Ser Gly Tyr Ser Phe Thr Ser Phe Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 272
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 272
Gln Ala Ser Gly Phe Ser Phe Ser Asp Tyr Tyr Met Ser Trp Val Arg
 1               5                  10                  15      


<210> 273
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 273
Ala Ala Ser Gly Tyr Ser Phe Ser Asp Tyr Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 274
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 274
Lys Ala Ser Gly Tyr Ser Phe Ser Thr Tyr Tyr Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 275
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 275
Glu Ala Ser Gly Tyr Thr Phe Ser Ala Phe Gln Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 276
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 276
Gln Ala Ser Gly Phe Ser Phe Ser Asn Phe Tyr Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 277
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 277
Lys Ala Ser Gly Phe Thr Phe Ser Ala Phe Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 278
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 278
Lys Ala Ser Gly Tyr Thr Phe Ser Thr Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 279
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 279
Ala Ala Ser Gly Tyr Ser Phe Ser Thr Tyr Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 280
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 280
Thr Ala Ser Gly Phe Ser Phe Ser Ala Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 281
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 281
Ala Ala Ser Gly Phe Ser Phe Ser Asn Tyr Tyr Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 282
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 282
Glu Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Met Tyr Trp Met Arg
 1               5                  10                  15      


<210> 283
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 283
Lys Ala Ser Gly Tyr Thr Phe Ser Asp Phe Ala Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 284
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 284
Lys Ala Ser Gly Tyr Ser Phe Thr Asn Phe Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 285
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 285
Ala Ala Ser Gly Tyr Ser Phe Ser Tyr Tyr Gly Met Tyr Trp Val Arg
 1               5                  10                  15      


<210> 286
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 286
Glu Ala Ser Gly Tyr Ser Phe Ser Ala Phe Gly Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 287
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 287
Lys Thr Ser Gly Tyr Thr Phe Ser Ala Phe Gln Ile Tyr Trp Val Arg
 1               5                  10                  15      


<210> 288
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 288
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Gly Met Tyr Trp Met Arg
 1               5                  10                  15      


<210> 289
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 289
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Thr Ile Ser Trp Val Arg
 1               5                  10                  15      


<210> 290
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 290
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Thr Ile Asn Trp Val Arg
 1               5                  10                  15      


<210> 291
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 291
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ser Ile Asn Trp Val Arg
 1               5                  10                  15      


<210> 292
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 292
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Ser Ile Asn Trp Val Arg
 1               5                  10                  15      


<210> 293
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 293
Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg
 1               5                  10                  15      


<210> 294
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Heavy Chain CDR1 Antibody Region

<400> 294
Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr Ser Ile Ser Trp Val Arg
 1               5                  10                  15      


<210> 295
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      CDR3 Antibody Region

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = V, A or G

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = W or Y

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = D, G, S or N

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = S, T or N

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = S, N, Y, D or T

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = P, H, A, D or S

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = P, A, S, R or G

<221> VARIANT        
<222> (12)...(12)
<223> Xaa = V, L or S

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = A, V, M, I, L or T

<221> VARIANT        
<222> (16)...(16)
<223> Xaa = G or D

<400> 295
Tyr Tyr Cys Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Gly Xaa
 1               5                  10                  15      


<210> 296
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      shorter CDR3 Antibody Region

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = V, A or G

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = W or Y

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = D, G, S or N

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = S, T or N

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S, N, Y, D or T

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = P, H, A, D or S

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = P, A, S, R or G

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = V, L or S

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = A, V, M, I, L or T

<400> 296
Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1               5                  10  


<210> 297
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      CDR3 Antibody Region

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = V, A or G

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = W or Y

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = D, G, S or N

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = S, T or N

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = S, N, Y, D or T

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = P, H, A, D or S

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = P, A, S, R or G

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = A, C, M, I, L or T

<400> 297
Tyr Tyr Cys Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Xaa Phe Gly Xaa
 1               5                  10                  15      


<210> 298
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      shorter CDR3 Antibody Region

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = V, A or G

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = W or Y

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = D, G, S or N

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = S, T or N

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S, N, Y, D or T

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = P, H, A, D or S

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = P, A, S, R or G

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = A, V, M, I, L or T

<400> 298
Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Xaa
 1               5                  10  


<210> 299
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      CDR3 Antibody Region

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = V, A or G

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = D, G, S or N

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = S, T or N

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = S, N, Y, D or T

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = P, H, A, D or S

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = P, A, S, R or G

<221> VARIANT        
<222> (13)...(13)
<223> Xaa = A, V, M, I, L or T

<400> 299
Tyr Tyr Cys Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Xaa Phe Gly Gly
 1               5                  10                  15      


<210> 300
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      shorter CDR3 Antibody Region

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = V, A or G

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = D, G, S or N

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = S, T or N

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S, N, Y, D or T

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = P, H, A, D or S

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = P, A, S, R or G

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = A, V, M, I, L or T

<400> 300
Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Xaa
 1               5                  10  


<210> 301
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 & AX213 Light Chain CDR3 Antibody Region

<400> 301
Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 302
<211> 48
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 & AX213 Light Chain CDR3 Antibody Region

<400> 302
tactactgcc aggtatggga cagctctcct cctgtggtgt tcggtggt              48

<210> 303
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 & AX213 Light Chain shorter CDR3 Antibody
      Region

<400> 303
Gln Val Trp Asp Ser Ser Pro Pro Val Val
 1               5                  10  


<210> 304
<211> 30
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 & AX213 Light Chain shorter CDR3 Antibody
      Region

<400> 304
caggtatggg acagctctcc tcctgtggtg                                  30

<210> 305
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 305
Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro Val Ala Phe Gly Gly
 1               5                  10                  15      


<210> 306
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 306
Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro Leu Val Phe Gly Gly
 1               5                  10                  15      


<210> 307
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 307
Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro Leu Ala Phe Gly Gly
 1               5                  10                  15      


<210> 308
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 308
Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Pro Pro Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 309
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 309
Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro Val Met Phe Gly Gly
 1               5                  10                  15      


<210> 310
<211> 14
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 310
Tyr Tyr Cys Gln Gly Trp Asp Ser Ser Pro Thr Phe Gly Gly
 1               5                  10                  


<210> 311
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 311
Tyr Tyr Cys Gln Val Trp Asp Asn Ser Pro Pro Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 312
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 312
Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Pro Pro Val Thr Phe Gly Asp
 1               5                  10                  15      


<210> 313
<211> 14
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 313
Tyr Tyr Cys Gln Gln Ser Gly Ser Tyr Leu Thr Phe Gly Gly
 1               5                  10                  


<210> 314
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 314
Tyr Tyr Cys Gln Val Trp Asp Ser Tyr His Ala Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 315
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 315
Tyr Tyr Cys Gln Val Trp Gly Ser Tyr His Ala Val Met Phe Gly Gly
 1               5                  10                  15      


<210> 316
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 316
Tyr Tyr Cys Gln Val Trp Gly Ser Tyr His Ser Val Met Phe Gly Gly
 1               5                  10                  15      


<210> 317
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 317
Tyr Tyr Cys Gln Val Trp Asp Thr Asp His Ser Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 318
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 318
Tyr Tyr Cys Gln Val Trp Asp Thr Asp His Ala Val Ala Phe Gly Gly
 1               5                  10                  15      


<210> 319
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 319
Tyr Tyr Cys Gln Val Trp Asp Ser Ser His Ser Val Ile Phe Gly Gly
 1               5                  10                  15      


<210> 320
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 320
Tyr Tyr Cys Gln Val Trp Asp Ser Tyr Pro Pro Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 321
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 321
Tyr Tyr Cys Gln Val Trp Asp Ser Asp His Ala Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 322
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 322
Tyr Tyr Cys Gln Val Trp Gly Ser Asn His Ala Ser Leu Phe Gly Gly
 1               5                  10                  15      


<210> 323
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 323
Tyr Tyr Cys Gln Val Trp Gly Ser Thr Ala Arg Val Ala Phe Gly Gly
 1               5                  10                  15      


<210> 324
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 324
Tyr Tyr Cys Gln Val Trp Asn Ser Thr Pro Pro Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 325
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 325
Tyr Tyr Cys Gln Val Trp Ser Ser Ser Pro Pro Val Ile Phe Gly Gly
 1               5                  10                  15      


<210> 326
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 326
Tyr Tyr Cys Gln Val Trp Ser Ser Ser Pro Pro Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 327
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 327
Tyr Tyr Cys Gln Val Trp Ser Ser Asn His Ala Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 328
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 328
Tyr Tyr Cys Gln Val Trp Gly Ser Asn Pro Pro Val Ala Phe Gly Gly
 1               5                  10                  15      


<210> 329
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 329
Tyr Tyr Cys Gln Val Trp Asp Ser Thr Pro Pro Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 330
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 330
Tyr Tyr Cys Gln Val Trp Asp Ser Asn Pro Pro Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 331
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 331
Tyr Tyr Cys Gln Gly Tyr Ser Ser Asn Asp Gly Val Ile Phe Gly Gly
 1               5                  10                  15      


<210> 332
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 332
Tyr Tyr Cys Gln Val Trp Gly Ser Asn His Ser Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 333
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 333
Tyr Tyr Cys Gln Val Trp Asp Ser Asn His Ser Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 334
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR3 Antibody Region

<400> 334
Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Ala Val Val Phe Gly Gly
 1               5                  10                  15      


<210> 335
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      CDR2 Antibody Region

<221> VARIANT        
<222> (5)...(5)
<223> Xaa = S or A

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = T, A or S

<400> 335
Leu Ile Tyr Asp Xaa Ser Asn Arg Ala Xaa Gly Ile Pro
 1               5                  10              


<210> 336
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      shorter CDR2 Antibody Region

<221> VARIANT        
<222> (2)...(2)
<223> Xaa = S or A

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = T, A or S

<400> 336
Asp Xaa Ser Asn Arg Ala Xaa
 1               5          


<210> 337
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      CDR2 Antibody Region

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = S or A

<221> VARIANT        
<222> (10)...(10)
<223> Xaa = T, A or S

<400> 337
Leu Ile Tyr Asp Ala Xaa Asn Arg Ala Xaa Gly Ile Pro
 1               5                  10              


<210> 338
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      shorter CDR2 Antibody Region

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = S or A

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = T, A or S

<400> 338
Asp Ala Xaa Asn Arg Ala Xaa
 1               5          


<210> 339
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 and AX132 Light Chain CDR2 Antibody Region

<400> 339
Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
 1               5                  10              


<210> 340
<211> 39
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 and AX132 Light Chain CDR2 Antibody Region

<400> 340
ctgatctacg acgcctctaa ccgtgccacc ggtatccca                        39

<210> 341
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 and AX132 Light Chain shorter CDR2 Antibody
      Region

<400> 341
Asp Ala Ser Asn Arg Ala Thr
 1               5          


<210> 342
<211> 21
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 and AX132 Light Chain shorter CDR2 Antibody
      Region

<400> 342
gacgcctcta accgtgccac c                                           21

<210> 343
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR2 Antibody Region

<400> 343
Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
 1               5                  10              


<210> 344
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR2 Antibody Region

<400> 344
Leu Ile Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro
 1               5                  10              


<210> 345
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR2 Antibody Region

<400> 345
Leu Ile Tyr Asp Ala Ser Asn Arg Ala Ala Gly Ile Pro
 1               5                  10              


<210> 346
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR2 Antibody Region

<400> 346
Leu Ile Tyr Asp Ala Ser Asn Arg Ala Ser Gly Ile Pro
 1               5                  10              


<210> 347
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      CDR1 Antibody Region

<221> VARIANT        
<222> (4)...(4)
<223> Xaa = R or Q

<221> VARIANT        
<222> (9)...(9)
<223> Xaa = V or I

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = T or S

<221> VARIANT        
<222> (14)...(14)
<223> Xaa = N, S or T

<400> 347
Ile Thr Cys Xaa Ala Ser Gln Tyr Xaa Gly Xaa Tyr Leu Xaa Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 348
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus sequence for AX213 and AX132 Light Chain
      shorter CDR1 Antibody Region

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = R or Q

<221> VARIANT        
<222> (6)...(6)
<223> Xaa = V or I

<221> VARIANT        
<222> (8)...(8)
<223> Xaa = T or S

<221> VARIANT        
<222> (11)...(11)
<223> Xaa = S or T

<400> 348
Xaa Ala Ser Gln Tyr Xaa Gly Xaa Tyr Leu Xaa
 1               5                  10      


<210> 349
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 and AX132 Light Chain CDR1 Antibody Region

<400> 349
Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr Leu Asn Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 350
<211> 51
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 and AX132 Light Chain CDR1 Antibody Region

<400> 350
atcacctgcc gtgcctctca gtatgtcggc agctacctga actggtatca g          51

<210> 351
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 and AX132 Light Chain shorter CDR1 Antibody
      Region

<400> 351
Arg Ala Ser Gln Tyr Val Gly Ser Tyr Leu Asn
 1               5                  10      


<210> 352
<211> 33
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 and AX132 Light Chain shorter CDR1 Antibody
      Region

<400> 352
cgtgcctctc agtatgtcgg cagctacctg aac                              33

<210> 353
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR1 Antibody Region

<400> 353
Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Thr Tyr Leu Asn Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 354
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR1 Antibody Region

<400> 354
Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gly Ser Tyr Leu Asn Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 355
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR1 Antibody Region

<400> 355
Ile Thr Cys Arg Ala Ser Gln Ala Ile Ser Asn Tyr Leu Thr Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 356
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR1 Antibody Region

<400> 356
Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr Leu Thr Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 357
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR1 Antibody Region

<400> 357
Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Asn Tyr Leu Asn Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 358
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR1 Antibody Region

<400> 358
Ile Thr Cys Gln Ala Ser Gln Tyr Val Gly Ser Tyr Leu Ser Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 359
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Light Chain CDR1 Antibody Region

<400> 359
Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr Leu Ser Trp Tyr
 1               5                  10                  15      
Gln
    


<210> 360
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 360
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 361
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 361
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser
        115             


<210> 362
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 362
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Asn Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 363
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 363
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Asn Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser
        115             


<210> 364
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 364
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Ser Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 365
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 365
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Gln
            20                  25                  30          
Gly Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 366
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 366
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Ser Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gln Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 367
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 367
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Asn Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 368
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 368
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Gln Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 369
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 369
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Thr Asn Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 370
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 370
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ser Tyr Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 371
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 371
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Ala Asn Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Ser Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 372
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 372
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Tyr Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 373
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 373
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Gln Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg His Arg Val Gly Tyr Ser Leu Asp Phe Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 374
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 374
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr His Tyr Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 375
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 375
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Tyr Tyr Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Ser Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr His Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 376
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 376
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ala Tyr Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Phe Ala Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 377
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 377
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Gln Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Asp Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 378
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 378
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ala Phe Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 379
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 379
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Ala Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 380
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 380
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Thr Ile Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg His Arg Val Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 381
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 381
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ser Phe Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Ser Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 382
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 382
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Thr Phe Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 383
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 383
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Gln Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Phe Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Asn Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 384
<211> 119
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 384
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Tyr Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Ser Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110         
Val Thr Val Ser Ser Ala Ser
        115                 


<210> 385
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 385
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 386
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 386
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ala Asn Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser His Val Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 387
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 387
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ser Asn Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 388
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 388
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Ser Ile Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg His Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 389
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 389
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln Gln Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 390
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 390
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Thr Tyr Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Glu Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 391
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 391
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Ser Tyr Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 392
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 392
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Tyr Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Asp Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 393
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 393
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Thr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Gln Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gln Arg Val Gly Tyr Asn Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 394
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 394
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Gln Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gln Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Glu Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 395
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 395
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ser Asn Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Gln Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gln Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 396
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 396
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Gln Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Asp Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 397
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 397
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Asp Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 398
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 398
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ser Tyr Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 399
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 399
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Thr Tyr Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 400
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 400
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln Gln Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 401
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 401
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Leu Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Thr Phe Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 402
<211> 119
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 402
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Gly Gln Arg Leu Pro Pro Arg Tyr Gly
            20                  25                  30          
Tyr Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
        35                  40                  45              
Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe Gln
    50                  55                  60                  
Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65                  70                  75                  80  
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
                85                  90                  95      
Arg Tyr Arg Ser Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110         
Val Thr Val Ser Ser Ala Ser
        115                 


<210> 403
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 403
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Tyr Ser Arg Tyr
            20                  25                  30          
Thr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 404
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 404
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Tyr Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 405
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 405
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Trp Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 406
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 406
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Asp Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Asn Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Asp Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 407
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 407
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 408
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 408
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Thr Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg His Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 409
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 409
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Gln Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Asn Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 410
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 410
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Asp Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 411
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 411
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Phe Val Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 412
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 412
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Phe Ile Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 413
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 413
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Phe Leu Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 414
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 414
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Arg Ile Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 415
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 415
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Arg Phe Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 416
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 416
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Arg Leu Tyr Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 417
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 417
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Phe Ile Tyr Tyr Asp Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 418
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 418
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Lys Ile Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 419
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 419
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Tyr Leu Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 420
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 420
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Phe Ile Tyr Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 421
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 421
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Asn Leu Tyr Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 422
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 422
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ser Arg Gly Lys Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 423
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 423
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Ser Ile Gly Tyr Asn Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 424
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 424
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Arg Asp Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 425
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 425
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Ala Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Ser Asn Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Ala Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 426
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 426
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Asp Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 427
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 427
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30          
Gln Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 428
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 428
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Tyr Tyr
            20                  25                  30          
Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45              
Gly Arg Ile Ser Pro Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
    50                  55                  60                  
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 429
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 429
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ala Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 430
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 430
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Tyr
            20                  25                  30          
Gln Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Gly Ser Gly Gly Thr Lys Tyr Asp Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 431
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 431
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Tyr
            20                  25                  30          
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Gly Ser Gly Gly Thr Lys Tyr Asp Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 432
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 432
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Leu Thr Phe Thr Asp Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asn Pro Asp Ser Gly Ser Thr Lys Tyr Ala Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 433
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 433
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 434
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 434
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 435
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 435
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30          
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Ser Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 436
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 436
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Ser Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 437
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 437
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30          
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45              
Gly Arg Ile Ser Pro Gly Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
    50                  55                  60                  
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 438
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 438
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Gln Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asp Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 439
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 439
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Lys Gln Arg Trp His Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 440
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 440
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Ser Phe Ser Asn Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Leu Asp Arg Pro Arg Gln Arg Trp His Gln Leu Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 441
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 441
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Ser Ala Tyr
            20                  25                  30          
Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Ser Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 442
<211> 121
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 442
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Ser Phe Ser Ser Tyr
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Leu Asp Arg Pro Lys Gln Arg Val Gly Thr Lys Tyr Asn Gln Lys
    50                  55                  60                  
Phe Gln Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65                  70                  75                  80  
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95      
Cys Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100                 105                 110         
Thr Leu Val Thr Val Ser Ser Ala Ser
        115                 120     


<210> 443
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 443
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Ser Thr Phe
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Leu Asp Arg Pro Arg Gln Arg Trp Pro Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 444
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 444
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Asp Tyr
            20                  25                  30          
Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Leu Asp Arg Pro Lys Gln Arg Trp His Gln Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 445
<211> 121
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 445
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Asp Phe
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Arg Gln Arg Val Ala Pro Lys Tyr Asn Gln Lys
    50                  55                  60                  
Phe Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65                  70                  75                  80  
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95      
Cys Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100                 105                 110         
Thr Leu Val Thr Val Ser Ser Ala Ser
        115                 120     


<210> 446
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 446
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Gln Ala Ser Gly Tyr Ser Phe Thr Thr Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Ser Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 447
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 447
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asn Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Leu Asp Arg Pro Lys Gln Arg Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 448
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 448
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Phe
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Arg Gln Arg Trp His Gln Val Gln Arg Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 449
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 449
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Asn Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 450
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 450
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Tyr Ser Phe Thr Ala Phe
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Ser Ser Gly Gly Thr Asn Tyr Asn Glu Gln Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 451
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 451
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Arg Gln Arg Trp His Gln Val Gln Pro Lys Val
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 452
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 452
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Ala Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Asn Ser Gly Gly Thr Lys Gln Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 453
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 453
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Ser Phe
            20                  25                  30          
Gln Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Ser Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 454
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 454
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Phe
            20                  25                  30          
Ser Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Leu Asp Arg Pro Arg Gln Arg Trp His Gln Val Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 455
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 455
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Gln Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 456
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 456
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Gln Ala Ser Gly Tyr Thr Phe Thr Ala Phe
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 457
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 457
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Ser Phe Thr Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Gln Asp Arg Pro Lys Tyr Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 458
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 458
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Gln Ala Ser Gly Phe Thr Phe Ser Thr Tyr
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Ser Asn Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 459
<211> 121
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 459
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Ser Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Arg Gln Arg Trp Gly Thr Lys Tyr Asn Glu Lys
    50                  55                  60                  
Phe Gln Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65                  70                  75                  80  
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95      
Cys Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100                 105                 110         
Thr Leu Val Thr Val Ser Ser Ala Ser
        115                 120     


<210> 460
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 460
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Tyr Ser Phe Ser Asn Phe
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asn Pro Ser Asn Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 461
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 461
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Thr Ala Ser Asp Phe Ser Phe Ser Thr Phe
            20                  25                  30          
Ser Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Gln Pro Arg Gln Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 462
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 462
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Asp Phe
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Arg Gln Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Asp Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 463
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 463
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr Ser Phe
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Lys Gln Arg Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 464
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 464
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Gln Ala Ser Gly Phe Ser Phe Ser Asp Tyr
            20                  25                  30          
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Ser Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 465
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 465
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Ser Asp Tyr
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Lys Gln Arg Trp His Gln Val Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 466
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 466
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Thr Tyr
            20                  25                  30          
Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Asp Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 467
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 467
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Tyr Thr Phe Ser Ala Phe
            20                  25                  30          
Gln Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 468
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 468
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Gln Ala Ser Gly Phe Ser Phe Ser Asn Phe
            20                  25                  30          
Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 469
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 469
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Ala Phe
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Asp Asn Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 470
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 470
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Thr Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Asp Gln Pro Arg Gln Gly Gly Thr Asn Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 471
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 471
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Ser Thr Tyr
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Asn Asn Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 472
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 472
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Ser Ala Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Arg Gln Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 473
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 473
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn Tyr
            20                  25                  30          
Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 474
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 474
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Met Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 475
<211> 121
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 475
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asn Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Arg Pro Lys Gln Arg Trp Ala Pro Lys Tyr Asn Glu Lys
    50                  55                  60                  
Phe Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65                  70                  75                  80  
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95      
Cys Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100                 105                 110         
Thr Leu Val Thr Val Ser Ser Ala Ser
        115                 120     


<210> 476
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 476
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Phe
            20                  25                  30          
Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Ser Asp Gln Pro Arg Gln Arg Trp His Gln Val Gln Pro Lys Val
    50                  55                  60                  
Gln Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 477
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 477
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn Phe
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Gly Asn Gly Gly Thr Lys Gln Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 478
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 478
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Ser Tyr Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Ser Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 479
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 479
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Tyr Ser Phe Ser Ala Phe
            20                  25                  30          
Gly Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 480
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 480
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Ser Ala Phe
            20                  25                  30          
Gln Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Thr Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 481
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 481
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Asp Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Lys Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 482
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 482
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Lys Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 483
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 483
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Lys Ser Gly Trp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 484
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 484
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Lys Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Met
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 485
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 485
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Asn Tyr Gln Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 486
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 486
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 487
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 487
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Asn Tyr Gln Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Lys Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 488
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 488
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Ala Asp Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 489
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 489
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Glu Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 490
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 490
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Asp Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Lys Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 491
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 491
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Gln Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Lys Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 492
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 492
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Asp Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 493
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 493
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Tyr Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Lys Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 494
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 494
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Glu Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Lys Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 495
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 495
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Met Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Glu Asp Lys Phe
    50                  55                  60                  
Glu Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 496
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 496
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Asn Tyr Thr Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Tyr Arg Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 497
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 497
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Ser His Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 498
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 498
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Ser Ala Tyr
            20                  25                  30          
Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 499
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 499
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Ser Ala Tyr
            20                  25                  30          
Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Phe Leu Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 500
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 500
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Phe Leu Tyr Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 501
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 501
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Thr Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 502
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 502
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 503
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 503
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Thr Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 504
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 504
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Thr Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Asn Gly Gly Ser Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 505
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 505
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Thr Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Arg Val Gly Tyr Ser Phe Asp Asn Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 506
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 506
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ser Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 507
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 507
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Thr Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Gln Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 508
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 508
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Ser Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Asn Gly Gly Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60                  
Gln Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 509
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 509
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 510
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Heavy Antibody Region

<400> 510
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Tyr Ile Asp Pro Gly Ser Gly Gly Thr Arg Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Ser Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gln Arg Val Gly Tyr Ser Leu Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 511
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 511
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 512
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 512
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Thr Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 513
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 513
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Thr Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 514
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 514
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 515
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 515
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Leu Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 516
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 516
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Leu Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 517
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 517
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 518
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 518
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Met Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 519
<211> 106
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 519
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ala Ile Ser Asn Tyr
            20                  25                  30          
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Trp Asp Ser Ser Pro Thr
                85                  90                  95      
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105     


<210> 520
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 520
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Thr Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Leu Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 521
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 521
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 522
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 522
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Thr Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Asn Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 523
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 523
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 524
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 524
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Thr Phe Gly Asp Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 525
<211> 106
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 525
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Asn Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Gly Ser Tyr Leu Thr
                85                  90                  95      
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105     


<210> 526
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 526
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Gln Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Tyr His Ala
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 527
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 527
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Gln Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Ala Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Gly Ser Tyr His Ala
                85                  90                  95      
Val Met Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 528
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 528
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Ala Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Gly Ser Tyr His Ser
                85                  90                  95      
Val Met Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 529
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 529
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Gln Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Ala Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Thr Asp His Ser
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 530
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 530
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Gln Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Thr Asp His Ala
                85                  90                  95      
Val Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 531
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 531
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser His Ser
                85                  90                  95      
Val Ile Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 532
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 532
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Tyr Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 533
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 533
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Tyr His Ala
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 534
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 534
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Asp His Ala
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 535
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 535
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Gly Ser Asn His Ala
                85                  90                  95      
Ser Leu Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 536
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 536
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Gly Ser Thr Ala Arg
                85                  90                  95      
Val Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 537
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 537
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asn Ser Thr Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 538
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 538
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Ser Ser Ser Pro Pro
                85                  90                  95      
Val Ile Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 539
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 539
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Ser Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 540
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 540
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Ser Ser Asn His Ala
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 541
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 541
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Gly Ser Asn Pro Pro
                85                  90                  95      
Val Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 542
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 542
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Thr Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 543
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 543
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Asn Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 544
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 544
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gly Tyr Ser Ser Asn Asp Gly
                85                  90                  95      
Val Ile Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 545
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 545
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Gly Ser Asn His Ser
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 546
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 546
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ala Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Asn His Ser
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 547
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 547
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Ala Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 548
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 548
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Ala
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 549
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Variable Light Antibody Region

<400> 549
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Leu Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 550
<211> 354
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 VARIABLE HEAVY ANTIBODY REGION

<400> 550
gaagtgcagc tgctggaatc tggtggtggt ctggtgcagc caggtggttc tctgcgtctg 60
tcttgcaagg cctctggtta caccttctct tcttacggga tgtactgggt gcgtcaggca 120
ccaggtaagg gtctggaatg gatcggttgg atcgacccag gcagcggtgg caccaagtac 180
aacgaaaagt tcaagggtaa ggccaccatc tctagagaca actctaagaa caccctgtac 240
ttgcagatga actctctgcg tgccgaggac actgcagtgt actactgcgc ccgtgaacgt 300
tacggttact acttcgacta ctggggtcag ggtacgctgg tgactgtctc gagc       354

<210> 551
<211> 324
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 VARIABLE HEAVY ANTIBODY REGION

<400> 551
gaaatcgtgc tgacccagtc tccagccacc ctgtctctgt ctcccgggga acgtgccacc 60
atcacctgcc gtgcctctca gtatgtcggc agctacctga actggtatca gcagaagcca 120
ggtcaggcgc cacgtctgct gatctacgac gcctctaacc gtgccaccgg tatcccagcc 180
cgtttctctg gttctggttc tggcaccgac ttcaccctga ccatctcttc tctggaacca 240
gaagacttcg ccgtgtacta ctgccaggta tgggacagct ctcctcctgt ggtgttcggt 300
ggtggtacca aagtggagat caaa                                        324

<210> 552
<211> 226
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 FAB VHCH1 ANTIBODY REGION

<400> 552
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
        115                 120                 125             
Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
    130                 135                 140                 
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145                 150                 155                 160 
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                165                 170                 175     
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
            180                 185                 190         
Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
        195                 200                 205             
Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
    210                 215                 220                 
His Thr
225     


<210> 553
<211> 678
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 FAB VHCH1 ANTIBODY REGION

<400> 553
gaagtgcagc tgctggaatc tggtggtggt ctggtgcagc caggtggttc tctgcgtctg 60
tcttgcaagg cctctggtta caccttctct tcttacggga tgtactgggt gcgtcaggca 120
ccaggtaagg gtctggaatg gatcggttgg atcgacccag gcagcggtgg caccaagtac 180
aacgaaaagt tcaagggtaa ggccaccatc tctagagaca actctaagaa caccctgtac 240
ttgcagatga actctctgcg tgccgaggac actgcagtgt actactgcgc ccgtgaacgt 300
tacggttact acttcgacta ctggggtcag ggtacgctgg tgactgtctc gagcgcaagc 360
accaaaggcc catcggtatt ccccctggca ccctcctcca agagcacctc tgggggcaca 420
gcggccctgg gctgcctggt caaggactac ttccccgagc cggtgacggt gtcgtggaac 480
tcaggcgctc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 540
tactccctca gcagcgtggt gactgtgccc tccagcagct tgggcaccca gacctacatc 600
tgcaacgtga atcacaagcc cagcaacact aaggtggaca agaaagttga gcccaaatct 660
tgtgacaaaa ctcacaca                                               678

<210> 554
<211> 215
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 FAB VHCK ANTIBODY REGION

<400> 554
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala
            100                 105                 110         
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
        115                 120                 125             
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
    130                 135                 140                 
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
145                 150                 155                 160 
Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
                165                 170                 175     
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
            180                 185                 190         
Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
        195                 200                 205             
Ser Phe Asn Arg Gly Glu Cys
    210                 215 


<210> 555
<211> 645
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 FAB VHCK ANTIBODY REGION

<400> 555
gaaatcgtgc tgacccagtc tccagccacc ctgtctctgt ctcccgggga acgtgccacc 60
atcacctgcc gtgcctctca gtatgtcggc agctacctga actggtatca gcagaagcca 120
ggtcaggcgc cacgtctgct gatctacgac gcctctaacc gtgccaccgg tatcccagcc 180
cgtttctctg gttctggttc tggcaccgac ttcaccctga ccatctcttc tctggaacca 240
gaagacttcg ccgtgtacta ctgccaggta tgggacagct ctcctcctgt ggtgttcggt 300
ggtggtacca aagtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg 360
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 420
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 480
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 540
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 600
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                 645

<210> 556
<211> 444
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 IGG2 HEAVY CHAIN ANTIBODY REGION

<400> 556
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
            20                  25                  30          
Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Trp Ile Asp Pro Gly Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Arg Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
        115                 120                 125             
Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly
    130                 135                 140                 
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145                 150                 155                 160 
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                165                 170                 175     
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
            180                 185                 190         
Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser
        195                 200                 205             
Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys
    210                 215                 220                 
Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe
225                 230                 235                 240 
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
                245                 250                 255     
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe
            260                 265                 270         
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
        275                 280                 285             
Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr
    290                 295                 300                 
Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305                 310                 315                 320 
Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr
                325                 330                 335     
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
            340                 345                 350         
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
        355                 360                 365             
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
    370                 375                 380                 
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser
385                 390                 395                 400 
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
                405                 410                 415     
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
            420                 425                 430         
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 


<210> 557
<211> 1332
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 IGG2 HEAVY CHAIN ANTIBODY REGION

<400> 557
gaagtgcagc tgctggaatc tggtggtggt ctggtgcagc caggtggttc tctgcgtctg 60
tcttgcaagg cctctggtta caccttctct tcttacggga tgtactgggt gcgtcaggca 120
ccaggtaagg gtctggaatg gatcggttgg atcgacccag gcagcggtgg caccaagtac 180
aacgaaaagt tcaagggtaa ggccaccatc tctagagaca actctaagaa caccctgtac 240
ttgcagatga actctctgcg tgccgaggac actgcagtgt actactgcgc ccgtgaacgt 300
tacggttact acttcgacta ctggggtcag ggtacgctgg tgactgtctc gagcgctagc 360
accaagggcc catcggtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 420
gcggccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 480
tcaggcgctc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 540
tactccctca gcagcgtggt gaccgtgccc tccagcaact tcggcaccca gacctacacc 600
tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agacagttga gcgcaaatgt 660
tgtgtcgagt gcccaccgtg cccagcacca cctgtggcag gaccgtcagt cttcctcttc 720
cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac gtgcgtggtg 780
gtggacgtga gccacgaaga ccccgaggtc cagttcaact ggtacgtgga cggcgtggag 840
gtgcataatg ccaagacaaa gccacgggag gagcagttca acagcacgtt ccgtgtggtc 900
agcgtcctca ccgtcgtgca ccaggactgg ctgaacggca aggagtacaa gtgcaaggtc 960
tccaacaaag gcctcccagc ccccatcgag aaaaccatct ccaaaaccaa agggcagccc 1020
cgagaaccac aggtgtacac cctgccccca tcccgggagg agatgaccaa gaaccaggtc 1080
agcctgacct gcctggtcaa aggcttctac cccagcgaca tcgccgtgga gtgggagagc 1140
aatgggcagc cggagaacaa ctacaagacc acacctccca tgctggactc cgacggctcc 1200
ttcttcctct acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1260
tcatgctccg tgatgcatga ggctctgcac aaccactaca cacagaagag cctctccctg 1320
tctccgggta aa                                                     1332

<210> 558
<211> 215
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 IGG2 LIGHT CHAIN ANTIBODY REGION

<400> 558
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Thr Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala
            100                 105                 110         
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
        115                 120                 125             
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
    130                 135                 140                 
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
145                 150                 155                 160 
Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
                165                 170                 175     
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
            180                 185                 190         
Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
        195                 200                 205             
Ser Phe Asn Arg Gly Glu Cys
    210                 215 


<210> 559
<211> 645
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 IGG2 LIGHT CHAIN ANTIBODY REGION

<400> 559
gagattgtgc tgacccagag ccctgccacc ctgtccctga gccctggaga gagggctacc 60
atcacttgta gggcaagcca atatgtgggc acctacctga actggtatca acagaagcct 120
ggacaagccc caagactgct gatttatgat gccagcaaca gggctacagg catccctgcc 180
aggttctctg gctctggctc tggcacagac ttcaccctga ccatctcctc cttggaacct 240
gaggactttg ctgtctacta ctgtcaggtg tgggactcca gccctcctgt ggcatttgga 300
ggaggcacca aggtggagat taagcgtacg gtggctgcac catctgtctt catcttcccg 360
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 420
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 480
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 540
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 600
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                 645

<210> 560
<211> 4516
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX132 VECTOR

<400> 560
gcgcaacgca attaatgtga gttagctcac tcattaggca ccccaggctt tacactttat 60
gcttccggct cgtatgttgt gtggaattgt gagcggataa caatttaccg gttcttgtaa 120
ggaggaatta aaaaatgaaa aagtctttag tcctcaaagc ctccgtagcc gttgctaccc 180
tcgttccgat gctaagcttc gctgaaatcg tgctgaccca gtctccagcc accctgtctc 240
tgtctcccgg ggaacgtgcc accatcacct gccgtgcctc tcagtatgtc ggcagctacc 300
tgaactggta tcagcagaag ccaggtcagg cgccacgtct gctgatctac gacgcctcta 360
accgtgccac cggtatccca gcccgtttct ctggttctgg ttctggcacc gacttcaccc 420
tgaccatctc ttctctggaa ccagaagact tcgccgtgta ctactgccag gtatgggaca 480
gctctcctcc tgtggtgttc ggtggtggta ccaaagtgga gatcaaacgt acggtggctg 540
caccatctgt cttcatcttc ccgccatctg atgagcagtt gaaatctgga actgcctctg 600
ttgtgtgcct gctgaataac ttctatccca gagaggccaa agtacagtgg aaggtggata 660
acgccctcca atcgggtaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca 720
cctacagcct cagcagcacc ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct 780
acgcctgcga agtcacccat cagggcctga gctcgcccgt cacaaagagc ttcaacaggg 840
gagagtgttg ataaggcgcg ccacaatttc acagtaagga ggtttaactt atgaaaaaat 900
tattattcgc aattccttta gttgttcctt tctattctca ctccgctgga tccgaagtgc 960
agctgctgga atctggtggt ggtctggtgc agccaggtgg ttctctgcgt ctgtcttgca 1020
aggcctctgg ttacaccttc tcttcttacg ggatgtactg ggtgcgtcag gcaccaggta 1080
agggtctgga atggatcggt tggatcgacc caggcagcgg tggcaccaag tacaacgaaa 1140
agttcaaggg taaggccacc atctctagag acaactctaa gaacaccctg tacttgcaga 1200
tgaactctct gcgtgccgag gacactgcag tgtactactg cgcccgtgaa cgttacggtt 1260
actacttcga ctactggggt cagggtacgc tggtgactgt ctcgagcgca agcaccaaag 1320
gcccatcggt attccccctg gcaccctcct ccaagagcac ctctgggggc acagcggccc 1380
tgggctgcct ggtcaaggac tacttccccg agccggtgac ggtgtcgtgg aactcaggcg 1440
ctctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga ctctactccc 1500
tcagcagcgt ggtgactgtg ccctccagca gcttgggcac ccagacctac atctgcaacg 1560
tgaatcacaa gcccagcaac actaaggtgg acaagaaagt tgagcccaaa tcttgtgaca 1620
aaactcacac agcggccgct tatccatacg acgtaccaga ctacgcagga ggtcatcacc 1680
atcatcacca ttagagatct ggaggaggtg aggagaagtc ccggctgttg gagaaggaga 1740
accgtgaact ggaaaagatc attgctgaga aagaggagcg tgtctctgaa ctgcgccatc 1800
aactccagtc tgtaggaggt tgttaataag tcgacctcga ccaattcgcc ctatagtgag 1860
tcgtattacg cgcgctcact ggccgtcgtt ttacaacgtc gtgactggga aaaccctggc 1920
gttacccaac ttaatcgcct tgcagcacat ccccctttcg ccagctggcg taatagcgaa 1980
gaggcccgca ccgatcgccc ttcccaacag ttgcgcagcc tgaatggcga atgggacgcg 2040
ccctgtagcg gcgcattaag cgcggcgggt gtggtggtta cgcgcagcgt gaccgctaca 2100
cttgccagcg ccctagcgcc cgctcctttc gctttcttcc cttcctttct cgccacgttc 2160
gccggctttc cccgtcaagc tctaaatcgg gggctccctt tagggttccg atttagtgct 2220
ttacggcacc tcgaccccaa aaaacttgat tagggtgatg gttcacgtag tgggccatcg 2280
ccctgataga cggtttttcg ccctttgacg ttggagtcca cgttctttaa tagtggactc 2340
ttgttccaaa ctggaacaac actcaaccct atctcggtct attcttttga tttataaggg 2400
attttgccga tttcggccta ttggttaaaa aatgagctga tttaacaaaa atttaacgcg 2460
aattttaaca aaatattaac gcttacaatt taggtggcac ttttcgggga aatgtgcgcg 2520
gaacccctat ttgtttattt ttctaaatac attcaaatat gtatccgctc atgagacaat 2580
aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt caacatttcc 2640
gtgtcgccct tattcccttt tttgcggcat tttgccttcc tgtttttgct cacccagaaa 2700
cgctggtgaa agtaaaagat gctgaagatc agttgggtgc acgagtgggt tacatcgaac 2760
tggatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt tttccaatga 2820
tgagcacttt taaagttctg ctatgtggcg cggtattatc ccgtattgac gccgggcaag 2880
agcaactcgg tcgccgcata cactattctc agaatgactt ggttgagtac tcaccagtca 2940
cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct gccataacca 3000
tgagtgataa cactgcggcc aacttacttc tgacaacgat cggaggaccg aaggagctaa 3060
ccgctttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg gaaccggagc 3120
tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca atggcaacaa 3180
cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccggcaa caattaatag 3240
actggatgga ggcggataaa gttgcaggac cacttctgcg ctcggccctt ccggctggct 3300
ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc attgcagcac 3360
tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg agtcaggcaa 3420
ctatggatga acgaaataga cagatcgctg agataggtgc ctcactgatt aagcattggt 3480
aactgtcaga ccaagtttac tcatatatac tttagattga tttaaaactt catttttaat 3540
ttaaaaggat ctaggtgaag atcctttttg ataatctcat gaccaaaatc ccttaacgtg 3600
agttttcgtt ccactgagcg tcagaccccg tagaaaagat caaaggatct tcttgagatc 3660
ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta ccagcggtgg 3720
tttgtttgcc ggatcaagag ctaccaactc tttttccgaa ggtaactggc ttcagcagag 3780
cgcagatacc aaatactgtc cttctagtgt agccgtagtt aggccaccac ttcaagaact 3840
ctgtagcacc gcctacatac ctcgctctgc taatcctgtt accagtggct gctgccagtg 3900
gcgataagtc gtgtcttacc gggttggact caagacgata gttaccggat aaggcgcagc 3960
ggtcgggctg aacggggggt tcgtgcacac agcccagctt ggagcgaacg acctacaccg 4020
aactgagata cctacagcgt gagctatgag aaagcgccac gcttcccgaa gggagaaagg 4080
cggacaggta tccggtaagc ggcagggtcg gaacaggaga gcgcacgagg gagcttccag 4140
ggggaaacgc ctggtatctt tatagtcctg tcgggtttcg ccacctctga cttgagcgtc 4200
gatttttgtg atgctcgtca ggggggcgga gcctatggaa aaacgccagc aacgcggcct 4260
ttttacggtt cctggccttt tgctggcctt ttgctcacat gttctttcct gcgttatccc 4320
ctgattctgt ggataaccgt attaccgcct ttgagtgagc tgataccgct cgccgcagcc 4380
gaacgaccga gcgcagcgag tcagtgagcg aggaagcgga agagcgccca atacgcaaac 4440
cgcctctccc cgcgcgttgg ccgattcatt aatgcagctg gcacgacagg tttcccgact 4500
ggaaagcggg cagtga                                                 4516

<210> 561
<211> 354
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 VARIABLE HEAVY ANTIBODY REGION

<400> 561
caggtgcaat tgctggaatc tggtggtggt ctggtgcagc caggtggttc tctgcgtctg 60
tcttgcaagg ctagcggtta caccttctct cgctacggta tcaactgggt gcgtcaggca 120
ccaggtaagg gtctggaatg gatcggtcgg atcgacccag gtaacggtgg tactaggtac 180
aacgaaaagt tcaagggtaa ggccaccatc tctagagaca actctaagaa caccctgtac 240
ttgcagatga actctctgcg tgccgaggac actgcagtgt actactgcgc ccgtgcaaat 300
gacggttact ccttcgacta ctggggtcag ggtacgctgg tgactgtctc gagc       354

<210> 562
<211> 226
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 FAB VHCH1 ANTIBODY REGION

<400> 562
Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Asn Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
        115                 120                 125             
Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
    130                 135                 140                 
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145                 150                 155                 160 
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                165                 170                 175     
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
            180                 185                 190         
Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
        195                 200                 205             
Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
    210                 215                 220                 
His Thr
225     


<210> 563
<211> 678
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 FAB VHCH1 ANTIBODY REGION

<400> 563
caggtgcaat tgctggaatc tggtggtggt ctggtgcagc caggtggttc tctgcgtctg 60
tcttgcaagg ctagcggtta caccttctct cgctacggta tcaactgggt gcgtcaggca 120
ccaggtaagg gtctggaatg gatcggtcgg atcgacccag gtaacggtgg tactaggtac 180
aacgaaaagt tcaagggtaa ggccaccatc tctagagaca actctaagaa caccctgtac 240
ttgcagatga actctctgcg tgccgaggac actgcagtgt actactgcgc ccgtgcaaat 300
gacggttact ccttcgacta ctggggtcag ggtacgctgg tgactgtctc gagcgcaagc 360
accaaaggcc catcggtatt ccccctggca ccctcctcca agagcacctc tgggggcaca 420
gcggccctgg gctgcctggt caaggactac ttccccgagc cggtgacggt gtcgtggaac 480
tcaggcgctc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 540
tactccctca gcagcgtggt gactgtgccc tccagcagct tgggcaccca gacctacatc 600
tgcaacgtga atcacaagcc cagcaacact aaggtggaca agaaagttga gcccaaatct 660
tgtgacaaaa ctcacaca                                               678

<210> 564
<211> 444
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 IGG2 HEAVY CHAIN ANTIBODY REGION

<400> 564
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Arg Tyr
            20                  25                  30          
Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Ile Asp Pro Gly Asn Gly Gly Thr Arg Tyr Asn Glu Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ala Asn Asp Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
        115                 120                 125             
Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly
    130                 135                 140                 
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145                 150                 155                 160 
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                165                 170                 175     
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
            180                 185                 190         
Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser
        195                 200                 205             
Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys
    210                 215                 220                 
Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe
225                 230                 235                 240 
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
                245                 250                 255     
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe
            260                 265                 270         
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
        275                 280                 285             
Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr
    290                 295                 300                 
Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305                 310                 315                 320 
Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr
                325                 330                 335     
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
            340                 345                 350         
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
        355                 360                 365             
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
    370                 375                 380                 
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser
385                 390                 395                 400 
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
                405                 410                 415     
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
            420                 425                 430         
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 


<210> 565
<211> 1332
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 IGG2 HEAVY CHAIN ANTIBODY REGION

<400> 565
gaggtccaac ttttggagtc tggaggagga ctggtccaac ctggaggctc cctgagactg 60
tcctgtaagg catctggcta caccttcagc agatatggca tcaactgggt gagacaggct 120
cctggcaagg gattggagtg gattggcagg attgaccctg gcaatggagg caccagatac 180
aatgagaagt tcaagggcaa ggctaccatc agcagggaca acagcaagaa caccctctac 240
ctccaaatga actccctgag ggctgaggac acagcagtct actactgtgc cagggctaat 300
gatggctact cctttgacta ctggggacaa ggcaccctgg tgacagtgtc ctctgctagc 360
accaagggcc catcggtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 420
gcggccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 480
tcaggcgctc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 540
tactccctca gcagcgtggt gaccgtgccc tccagcaact tcggcaccca gacctacacc 600
tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agacagttga gcgcaaatgt 660
tgtgtcgagt gcccaccgtg cccagcacca cctgtggcag gaccgtcagt cttcctcttc 720
cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac gtgcgtggtg 780
gtggacgtga gccacgaaga ccccgaggtc cagttcaact ggtacgtgga cggcgtggag 840
gtgcataatg ccaagacaaa gccacgggag gagcagttca acagcacgtt ccgtgtggtc 900
agcgtcctca ccgtcgtgca ccaggactgg ctgaacggca aggagtacaa gtgcaaggtc 960
tccaacaaag gcctcccagc ccccatcgag aaaaccatct ccaaaaccaa agggcagccc 1020
cgagaaccac aggtgtacac cctgccccca tcccgggagg agatgaccaa gaaccaggtc 1080
agcctgacct gcctggtcaa aggcttctac cccagcgaca tcgccgtgga gtgggagagc 1140
aatgggcagc cggagaacaa ctacaagacc acacctccca tgctggactc cgacggctcc 1200
ttcttcctct acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1260
tcatgctccg tgatgcatga ggctctgcac aaccactaca cacagaagag cctctccctg 1320
tctccgggta aa                                                     1332

<210> 566
<211> 215
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX213 IGG2 LIGHT CHAIN ANTIBODY REGION

<400> 566
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Tyr Val Gly Ser Tyr
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Pro Pro
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala
            100                 105                 110         
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
        115                 120                 125             
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
    130                 135                 140                 
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
145                 150                 155                 160 
Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
                165                 170                 175     
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
            180                 185                 190         
Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
        195                 200                 205             
Ser Phe Asn Arg Gly Glu Cys
    210                 215 


<210> 567
<211> 645
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 IGG2 LIGHT CHAIN ANTIBODY REGION

<400> 567
gaaatcgtgc tgacccagtc tccagccacc ctgtctctgt ctcccgggga acgtgccacc 60
atcacctgcc gtgcctctca gtatgtcggc agctacctga actggtatca gcagaagcca 120
ggtcaggcgc cacgtctgct gatctacgac gcctctaacc gtgccaccgg tatcccagcc 180
cgtttctctg gttctggttc tggcaccgac ttcaccctga ccatctcttc tctggaacca 240
gaagacttcg ccgtgtacta ctgccaggta tgggacagct ctcctcctgt ggtgttcggt 300
ggtggtacca aagtggaaat caagcgtacg gtggctgcac catctgtatt catcttcccg 360
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 420
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 480
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 540
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 600
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                 645

<210> 568
<211> 645
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 IGG2 LIGHT CHAIN ANTIBODY REGION

<400> 568
gagattgtgc tgacccagag ccctgccacc ctgtccctga gccctggaga gagggctacc 60
atcacttgta gggcaagcca atatgtgggc tcctacctga actggtatca acagaagcct 120
ggacaagccc caagactgct gatttatgat gccagcaaca gggctacagg catccctgcc 180
aggttctctg gctctggctc tggcacagac ttcaccctga ccatctcctc cttggaacct 240
gaggactttg ctgtctacta ctgtcaggtg tgggactcca gccctcctgt ggtgtttgga 300
ggaggcacca aggtggagat taagcgtacg gtggctgcac catctgtctt catcttcccg 360
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 420
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 480
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 540
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 600
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                 645

<210> 569
<211> 4507
<212> DNA
<213> Artificial Sequence

<220> 
<223> AX213 VECTOR

<400> 569
gcgcaacgca attaatgtga gttagctcac tcattaggca ccccaggctt tacactttat 60
gcttccggct cgtatgttgt gtggaattgt gagcggataa caatttaccg gttcttgtaa 120
ggaggaatta aaaaatgaaa aagtctttag tcctcaaagc ctccgtagcc gttgctaccc 180
tcgttccgat gctaagcttc gctgaaatcg tgctgaccca gtctccagcc accctgtctc 240
tgtctcccgg ggaacgtgcc accatcacct gccgtgcctc tcagtatgtc ggcagctacc 300
tgaactggta tcagcagaag ccaggtcagg cgccacgtct gctgatctac gacgcctcta 360
accgtgccac cggtatccca gcccgtttct ctggttctgg ttctggcacc gacttcaccc 420
tgaccatctc ttctctggaa ccagaagact tcgccgtgta ctactgccag gtatgggaca 480
gctctcctcc tgtggtgttc ggtggtggta ccaaagtgga gatcaaacgt acggtggctg 540
caccatctgt cttcatcttc ccgccatctg atgagcagtt gaaatctgga actgcctctg 600
ttgtgtgcct gctgaataac ttctatccca gagaggccaa agtacagtgg aaggtggata 660
acgccctcca atcgggtaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca 720
cctacagcct cagcagcacc ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct 780
acgcctgcga agtcacccat cagggcctga gctcgcccgt cacaaagagc ttcaacaggg 840
gagagtgttg ataaggcgcg ccacaatttc acagtaagga ggtttaactt atgaaaaaat 900
tattattcgc aattccttta gttgttcctt tctattctca ctcccaggtg caattgctgg 960
aatctggtgg tggtctggtg cagccaggtg gttctctgcg tctgtcttgc aaggctagcg 1020
gttacacctt ctctcgctac ggtatcaact gggtgcgtca ggcaccaggt aagggtctgg 1080
aatggatcgg tcggatcgac ccaggtaacg gtggtactag gtacaacgaa aagttcaagg 1140
gtaaggccac catctctaga gacaactcta agaacaccct gtacttgcag atgaactctc 1200
tgcgtgccga ggacactgca gtgtactact gcgcccgtgc aaatgacggt tactccttcg 1260
actactgggg tcagggtacg ctggtgactg tctcgagcgc aagcaccaaa ggcccatcgg 1320
tattccccct ggcaccctcc tccaagagca cctctggggg cacagcggcc ctgggctgcc 1380
tggtcaagga ctacttcccc gagccggtga cggtgtcgtg gaactcaggc gctctgacca 1440
gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc ctcagcagcg 1500
tggtgactgt gccctccagc agcttgggca cccagaccta catctgcaac gtgaatcaca 1560
agcccagcaa cactaaggtg gacaagaaag ttgagcccaa atcttgtgac aaaactcaca 1620
cagcggccgc ttatccatac gacgtaccag actacgcagg aggtcatcac catcatcacc 1680
attagagatc tggaggaggt gaggagaagt cccggctgtt ggagaaggag aaccgtgaac 1740
tggaaaagat cattgctgag aaagaggagc gtgtctctga actgcgccat caactccagt 1800
ctgtaggagg ttgttaataa gtcgacctcg accaattcgc cctatagtga gtcgtattac 1860
gcgcgctcac tggccgtcgt tttacaacgt cgtgactggg aaaaccctgg cgttacccaa 1920
cttaatcgcc ttgcagcaca tccccctttc gccagctggc gtaatagcga agaggcccgc 1980
accgatcgcc cttcccaaca gttgcgcagc ctgaatggcg aatgggacgc gccctgtagc 2040
ggcgcattaa gcgcggcggg tgtggtggtt acgcgcagcg tgaccgctac acttgccagc 2100
gccctagcgc ccgctccttt cgctttcttc ccttcctttc tcgccacgtt cgccggcttt 2160
ccccgtcaag ctctaaatcg ggggctccct ttagggttcc gatttagtgc tttacggcac 2220
ctcgacccca aaaaacttga ttagggtgat ggttcacgta gtgggccatc gccctgatag 2280
acggtttttc gccctttgac gttggagtcc acgttcttta atagtggact cttgttccaa 2340
actggaacaa cactcaaccc tatctcggtc tattcttttg atttataagg gattttgccg 2400
atttcggcct attggttaaa aaatgagctg atttaacaaa aatttaacgc gaattttaac 2460
aaaatattaa cgcttacaat ttaggtggca cttttcgggg aaatgtgcgc ggaaccccta 2520
tttgtttatt tttctaaata cattcaaata tgtatccgct catgagacaa taaccctgat 2580
aaatgcttca ataatattga aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc 2640
ttattccctt ttttgcggca ttttgccttc ctgtttttgc tcacccagaa acgctggtga 2700
aagtaaaaga tgctgaagat cagttgggtg cacgagtggg ttacatcgaa ctggatctca 2760
acagcggtaa gatccttgag agttttcgcc ccgaagaacg ttttccaatg atgagcactt 2820
ttaaagttct gctatgtggc gcggtattat cccgtattga cgccgggcaa gagcaactcg 2880
gtcgccgcat acactattct cagaatgact tggttgagta ctcaccagtc acagaaaagc 2940
atcttacgga tggcatgaca gtaagagaat tatgcagtgc tgccataacc atgagtgata 3000
acactgcggc caacttactt ctgacaacga tcggaggacc gaaggagcta accgcttttt 3060
tgcacaacat gggggatcat gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag 3120
ccataccaaa cgacgagcgt gacaccacga tgcctgtagc aatggcaaca acgttgcgca 3180
aactattaac tggcgaacta cttactctag cttcccggca acaattaata gactggatgg 3240
aggcggataa agttgcagga ccacttctgc gctcggccct tccggctggc tggtttattg 3300
ctgataaatc tggagccggt gagcgtgggt ctcgcggtat cattgcagca ctggggccag 3360
atggtaagcc ctcccgtatc gtagttatct acacgacggg gagtcaggca actatggatg 3420
aacgaaatag acagatcgct gagataggtg cctcactgat taagcattgg taactgtcag 3480
accaagttta ctcatatata ctttagattg atttaaaact tcatttttaa tttaaaagga 3540
tctaggtgaa gatccttttt gataatctca tgaccaaaat cccttaacgt gagttttcgt 3600
tccactgagc gtcagacccc gtagaaaaga tcaaaggatc ttcttgagat cctttttttc 3660
tgcgcgtaat ctgctgcttg caaacaaaaa aaccaccgct accagcggtg gtttgtttgc 3720
cggatcaaga gctaccaact ctttttccga aggtaactgg cttcagcaga gcgcagatac 3780
caaatactgt ccttctagtg tagccgtagt taggccacca cttcaagaac tctgtagcac 3840
cgcctacata cctcgctctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt 3900
cgtgtcttac cgggttggac tcaagacgat agttaccgga taaggcgcag cggtcgggct 3960
gaacgggggg ttcgtgcaca cagcccagct tggagcgaac gacctacacc gaactgagat 4020
acctacagcg tgagctatga gaaagcgcca cgcttcccga agggagaaag gcggacaggt 4080
atccggtaag cggcagggtc ggaacaggag agcgcacgag ggagcttcca gggggaaacg 4140
cctggtatct ttatagtcct gtcgggtttc gccacctctg acttgagcgt cgatttttgt 4200
gatgctcgtc aggggggcgg agcctatgga aaaacgccag caacgcggcc tttttacggt 4260
tcctggcctt ttgctggcct tttgctcaca tgttctttcc tgcgttatcc cctgattctg 4320
tggataaccg tattaccgcc tttgagtgag ctgataccgc tcgccgcagc cgaacgaccg 4380
agcgcagcga gtcagtgagc gaggaagcgg aagagcgccc aatacgcaaa ccgcctctcc 4440
ccgcgcgttg gccgattcat taatgcagct ggcacgacag gtttcccgac tggaaagcgg 4500
gcagtga                                                           4507

<210> 570
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCKS9 Internal Processing Site

<400> 570
Ser Ser Val Phe Ala Gln
 1               5      


<210> 571
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCKS9 Internal Processing Site

<400> 571
Ser Ile Pro Trp Asn Leu
 1               5      


<210> 572
<211> 330
<212> PRT
<213> Artificial Sequence

<220> 
<223> Sequence containing Fc domain of IgG1

<400> 572
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1               5                  10                  15      
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
            20                  25                  30          
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
        35                  40                  45              
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50                  55                  60                  
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65                  70                  75                  80  
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
                85                  90                  95      
Lys Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
            100                 105                 110         
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
        115                 120                 125             
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
    130                 135                 140                 
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145                 150                 155                 160 
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
                165                 170                 175     
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
            180                 185                 190         
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
        195                 200                 205             
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
    210                 215                 220                 
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225                 230                 235                 240 
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
                245                 250                 255     
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
            260                 265                 270         
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
        275                 280                 285             
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
    290                 295                 300                 
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305                 310                 315                 320 
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
                325                 330 


<210> 573
<211> 326
<212> PRT
<213> Artificial Sequence

<220> 
<223> Sequence containing Fc domain of IgG2

<400> 573
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1               5                  10                  15      
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
            20                  25                  30          
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
        35                  40                  45              
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50                  55                  60                  
Leu Ser Ser Val Val Thr Val Thr Ser Ser Asn Phe Gly Thr Gln Thr
65                  70                  75                  80  
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
                85                  90                  95      
Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro
            100                 105                 110         
Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
        115                 120                 125             
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
    130                 135                 140                 
Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
145                 150                 155                 160 
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
                165                 170                 175     
Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp
            180                 185                 190         
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
        195                 200                 205             
Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu
    210                 215                 220                 
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
225                 230                 235                 240 
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
                245                 250                 255     
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
            260                 265                 270         
Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
        275                 280                 285             
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
    290                 295                 300                 
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
305                 310                 315                 320 
Ser Leu Ser Pro Gly Lys
                325     


<210> 574
<211> 327
<212> PRT
<213> Artificial Sequence

<220> 
<223> Sequence containing Fc domain of IgG4

<400> 574
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1               5                  10                  15      
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
            20                  25                  30          
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
        35                  40                  45              
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50                  55                  60                  
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65                  70                  75                  80  
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
                85                  90                  95      
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro
            100                 105                 110         
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
        115                 120                 125             
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
    130                 135                 140                 
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145                 150                 155                 160 
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
                165                 170                 175     
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
            180                 185                 190         
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
        195                 200                 205             
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
    210                 215                 220                 
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225                 230                 235                 240 
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
                245                 250                 255     
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
            260                 265                 270         
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
        275                 280                 285             
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
    290                 295                 300                 
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305                 310                 315                 320 
Leu Ser Leu Ser Leu Gly Lys
                325         


<210> 575
<211> 326
<212> PRT
<213> Artificial Sequence

<220> 
<223> Sequence containing Fc domain of IgG2m4

<400> 575
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1               5                  10                  15      
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
            20                  25                  30          
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
        35                  40                  45              
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50                  55                  60                  
Leu Ser Ser Val Val Thr Val Thr Ser Ser Asn Phe Gly Thr Gln Thr
65                  70                  75                  80  
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
                85                  90                  95      
Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro
            100                 105                 110         
Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
        115                 120                 125             
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
    130                 135                 140                 
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
145                 150                 155                 160 
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
                165                 170                 175     
Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
            180                 185                 190         
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
        195                 200                 205             
Ser Ser Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu
    210                 215                 220                 
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
225                 230                 235                 240 
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
                245                 250                 255     
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
            260                 265                 270         
Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
        275                 280                 285             
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
    290                 295                 300                 
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
305                 310                 315                 320 
Ser Leu Ser Pro Gly Lys
                325     


<210> 576
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 ANTIBODY EPITOPE

<400> 576
Pro Trp Asn Leu
 1              


<210> 577
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 ANTIBODY EPITOPE

<400> 577
Pro Gly Glu Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys
 1               5                  10                  15  


<210> 578
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 ANTIBODY EPITOPE

<400> 578
Gly Ala Ser Ser Asp Cys Ser Thr Cys
 1               5                  


<210> 579
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 ANTIBODY EPITOPE

<400> 579
Ser Ile Pro Trp
 1              


<210> 580
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 ANTIBODY EPITOPE

<400> 580
Asp His Arg Glu
 1              


<210> 581
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 ANTIBODY EPITOPE

<400> 581
His Arg Gln Ala Ser
 1               5  


<210> 582
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 ANTIBODY EPITOPE

<400> 582
Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser
 1               5                  10                  15  


<210> 583
<211> 22
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 AND VARIANT ANTIBODY HEAVY CHAIN FRAMEWORK 1
      REGION

<221> VARIANT        
<222> (1)...(1)
<223> Xaa = E or Q

<400> 583
Xaa Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys
            20          


<210> 584
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 AND VARIANT ANTIBODY HEAVY CHAIN FRAMEWORK 2
      REGION

<400> 584
Gln Ala Pro Gly Lys Gly Leu Glu
 1               5              


<210> 585
<211> 26
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 AND VARIANT ANTIBODY HEAVY CHAIN FRAMEWORK 3
      REGION

<400> 585
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser
 1               5                  10                  15      
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
            20                  25      


<210> 586
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 AND VARIANT ANTIBODY HEAVY CHAIN FRAMEWORK 4
      REGION

<400> 586
Gly Thr Leu Val Thr Val Ser Ser Ala Ser
 1               5                  10  


<210> 587
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 AND VARIANT ANTIBODY LIGHT CHAIN FRAMEWORK 1
      REGION

<400> 587
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr
            20  


<210> 588
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 AND VARIANT ANTIBODY LIGHT CHAIN FRAMEWORK 2
      REGION

<400> 588
Gln Lys Pro Gly Gln Ala Pro Arg Leu
 1               5                  


<210> 589
<211> 26
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 AND VARIANT ANTIBODY LIGHT CHAIN FRAMEWORK 3
      REGION

<400> 589
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
 1               5                  10                  15      
Ser Ser Leu Glu Pro Glu Asp Phe Ala Val
            20                  25      


<210> 590
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> AX132 AND VARIANT ANTIBODY LIGHT CHAIN FRAMEWORK 4
      REGION

<400> 590
Gly Thr Lys Val Glu Ile Lys
 1               5          


<210> 591
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus Antibody Variable Heavy Sequence

<221> VARIANT        
<222> (23)...(24)
<223> Xaa = K, A, E, Q or T at 23; A or T at 24

<221> VARIANT        
<222> (26)...(35)
<223> Xaa = G or D at 26; Y, F, L or Q at 27; T or S at
      28; F or Y at 29; S or T at 30; S, R, A, N, D, T
      or Y at 31; Y, F or Q at 32; G, S, T, A, Y, Q or W
      at 33; M, I, F, Y, N or Q at 34; Y, S, N, T, H or
      I at 35

<221> VARIANT        
<222> (37)...(37)
<223> Xaa = V or M

<221> VARIANT        
<222> (47)...(48)
<223> Xaa = W, S or Q at 47; I or V at 48

<221> VARIANT        
<222> (50)...(52)
<223> Xaa = W, R, Y, S, L or Q at 50; I or D at 51; D,
      N, R, Q or S at 52

<221> VARIANT        
<222> (54)...(68)
<223> Xaa = G, R, S, K, N or D at 54; S, N, Q, G or Y at
      55; G or R at 56; G, W, S or T at 57; T, H, P or S
      at 58; K, R, N, Q, S or Y at 59; Y, V, Q or L at
      60; N, Q, A, E, D,  Y, S or T at 61; E, Q, D, P, R
      or H at 62; K, Q or S at 63; F or V at 64; K, Q or
      E at 65; G, S or D at 66; K, R or Q at 67; A, V, F
      or T at 68

<221> VARIANT        
<222> (97)...(97)
<223> Xaa = A or S

<221> VARIANT        
<222> (99)...(105)
<223> Xaa = E, Y, A, G, S, H, Q or D at 99; R, K, F, N,
      H, D, S or Y at 100; Y, V, S, D, I, L, F or A at
      101; G, Y or A at 102; Y or W at 103; Y, S, N or D
      at 104; F or L at 105

<221> VARIANT        
<222> (107)...(107)
<223> Xaa = Y, N or F

<221> VARIANT        
<222> (110)...(110)
<223> Xaa = Q or E

<400> 591
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Arg Leu Ser Cys Xaa Xaa Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa
            20                  25                  30          
Xaa Xaa Xaa Trp Xaa Arg Gln Ala Pro Gly Lys Gly Leu Glu Xaa Xaa
        35                  40                  45              
Gly Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
    50                  55                  60                  
Xaa Xaa Xaa Xaa Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Trp Gly Xaa Gly Thr
            100                 105                 110         
Leu Val Thr Val Ser Ser Ala Ser
        115                 120 


<210> 592
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> Consensus Antibody Variable Light Sequence

<221> VARIANT        
<222> (24)...(24)
<223> Xaa = R or Q

<221> VARIANT        
<222> (29)...(29)
<223> Xaa = V or I

<221> VARIANT        
<222> (31)...(31)
<223> Xaa = T or S

<221> VARIANT        
<222> (34)...(34)
<223> Xaa = N, S or T

<221> VARIANT        
<222> (51)...(51)
<223> Xaa = S or A

<221> VARIANT        
<222> (56)...(56)
<223> Xaa = T, A or S

<221> VARIANT        
<222> (90)...(98)
<223> Xaa = V, A, or G at 90; W or Y at 91; D, G, S or N
      at 92; S, T or N at 93; S, N, Y, D or T at 94; P,
      H, A, D or S at 95; P, A, S, R or G at 96; V, L or
      S at 97; A, V, M, I, L or T at 98

<221> VARIANT        
<222> (101)...(101)
<223> Xaa = G or D

<400> 592
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1               5                  10                  15      
Glu Arg Ala Thr Ile Thr Cys Xaa Ala Ser Gln Tyr Xaa Gly Xaa Tyr
            20                  25                  30          
Leu Xaa Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45              
Tyr Asp Xaa Ser Asn Arg Ala Xaa Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80  
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa
                85                  90                  95      
Xaa Xaa Phe Gly Xaa Gly Thr Lys Val Glu Ile Lys
            100                 105             


<210> 593
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 593
Ala Leu Arg Ser Glu Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly
 1               5                  10                  15      
Thr Thr Ala Thr Phe
            20      


<210> 594
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 594
Arg Ser Glu Glu Asp Gly Leu
 1               5          


<210> 595
<211> 19
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 595
Arg Ser Glu Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr
 1               5                  10                  15      
Ala Thr Phe
            


<210> 596
<211> 24
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 596
Ala Pro Glu His Gly Thr Thr Ala Thr Phe His Arg Cys Ala Lys Asp
 1               5                  10                  15      
Pro Trp Arg Leu Pro Gly Thr Tyr
            20                  


<210> 597
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 597
Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr
 1               5                  10              


<210> 598
<211> 38
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 598
Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg Arg Leu Gln Ala
 1               5                  10                  15      
Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu His Val Phe His
            20                  25                  30          
Gly Leu Leu Pro Gly Phe
        35              


<210> 599
<211> 39
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 599
Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg Arg Leu Gln Ala
 1               5                  10                  15      
Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu His Val Phe His
            20                  25                  30          
Gly Leu Leu Pro Gly Phe Leu
        35                  


<210> 600
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 600
Ile Leu His Val Phe His Gly Leu Leu Pro Gly Phe Leu
 1               5                  10              


<210> 601
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 601
Met Ser Gly Asp Leu
 1               5  


<210> 602
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 602
Met Ser Gly Asp Leu Leu Glu
 1               5          


<210> 603
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 603
Leu Lys Leu Pro His Val Asp Tyr
 1               5              


<210> 604
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 604
Lys Leu Pro His Val Asp Tyr
 1               5          


<210> 605
<211> 19
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 605
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly
 1               5                  10                  15      
Gly Ser Leu
            


<210> 606
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 606
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly
 1               5                  10                  15      
Gly Ser Leu Val Glu
            20      


<210> 607
<211> 14
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 607
Thr Ser Ile Gln Ser Asp His Arg Glu Ile Glu Gly Arg Val
 1               5                  10                  


<210> 608
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 608
Ile Gln Ser Asp His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp
 1               5                  10                  15      
Phe
    


<210> 609
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 609
Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys
 1               5                  10                  15      
Asp Ser His Gly Thr His Leu
            20              


<210> 610
<211> 40
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 610
Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys
 1               5                  10                  15      
Asp Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala
            20                  25                  30          
Gly Val Ala Lys Gly Ala Ser Met
        35                  40  


<210> 611
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 611
Val Val Ser Gly Arg Asp Ala Gly Val Ala Lys Gly Ala Ser Met
 1               5                  10                  15  


<210> 612
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 612
Leu Arg Val Leu Asn Cys Gln Gly Lys Gly Thr Val Ser Gly Thr Leu
 1               5                  10                  15      


<210> 613
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 613
Ile Arg Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu
 1               5                  10                  15      


<210> 614
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 614
Arg Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu
 1               5                  10                  15  


<210> 615
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 615
Leu Leu Pro Leu Ala Gly Gly Tyr
 1               5              


<210> 616
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 616
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala
 1               5                  10      


<210> 617
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 617
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys
 1               5                  10              


<210> 618
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 618
Leu Ala Arg Ala Gly Val Val Leu
 1               5              


<210> 619
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 619
Ala Gly Val Val Leu
 1               5  


<210> 620
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 620
Ala Ala Gly Asn Phe
 1               5  


<210> 621
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 621
Asp Asp Ala Cys Leu
 1               5  


<210> 622
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 622
Pro Ala Ser Ala Pro Glu Val
 1               5          


<210> 623
<211> 22
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 623
Pro Ala Ser Ala Pro Glu Val Ile Thr Val Gly Ala Thr Asn Ala Gln
 1               5                  10                  15      
Asp Gln Pro Val Thr Leu
            20          


<210> 624
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 624
Val Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu
 1               5                  10              


<210> 625
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 625
Leu Gly Thr Asn Phe Gly Arg Cys
 1               5              


<210> 626
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 626
Leu Phe Ala Pro Gly Glu Asp
 1               5          


<210> 627
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 627
Gln Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala
 1               5                  10                  15  


<210> 628
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 628
Ser Ala Glu Pro Glu Leu Thr Leu
 1               5              


<210> 629
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 629
Ala Glu Pro Glu Leu Thr Leu
 1               5          


<210> 630
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 630
Leu Arg Gln Arg Leu Ile His Phe
 1               5              


<210> 631
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 631
Leu Arg Gln Arg Leu Ile His Phe Ser Ala Lys Asp Val Ile Asn Glu
 1               5                  10                  15      


<210> 632
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 632
Arg Leu Ile His Phe
 1               5  


<210> 633
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 633
Arg Leu Ile His Phe Ser Ala Lys Asp Val Ile Asn Glu
 1               5                  10              


<210> 634
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 634
Ser Ala Lys Asp Val Ile Asn Glu
 1               5              


<210> 635
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 635
Phe Pro Glu Asp Gln
 1               5  


<210> 636
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 636
Phe Pro Glu Asp Gln Arg Val Leu Thr Pro Asn Leu
 1               5                  10          


<210> 637
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 637
Val Leu Thr Pro Asn Leu
 1               5      


<210> 638
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 638
Leu Thr Pro Asn Leu
 1               5  


<210> 639
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 639
Ala Leu Pro Pro Ser Thr His Gly Ala Gly Trp Gln Leu
 1               5                  10              


<210> 640
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 640
Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr Gly
 1               5                  10                  15      
Cys Ser Ser His Trp
            20      


<210> 641
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> PCSK9 Fragment

<400> 641
Arg Val His Cys His Gln Gln Gly His Val Leu Thr Gly Cys Ser Ser
 1               5                  10                  15      
His Trp
        


<210> 642
<211> 692
<212> PRT
<213> Artificial Sequence

<220> 
<223> Human PCSK9

<400> 642
Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Leu
 1               5                  10                  15      
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu
            20                  25                  30          
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
        35                  40                  45              
Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala Thr Phe
    50                  55                  60                  
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65                  70                  75                  80  
Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg
                85                  90                  95      
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu
            100                 105                 110         
His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly
        115                 120                 125             
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu
    130                 135                 140                 
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg
145                 150                 155                 160 
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly
                165                 170                 175     
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp
            180                 185                 190         
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val
        195                 200                 205             
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp
    210                 215                 220                 
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225                 230                 235                 240 
Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn Cys Gln
                245                 250                 255     
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
            260                 265                 270         
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
        275                 280                 285             
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln Arg Leu
    290                 295                 300                 
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp
305                 310                 315                 320 
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
                325                 330                 335     
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
            340                 345                 350         
Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile
        355                 360                 365             
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly
    370                 375                 380                 
Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu
385                 390                 395                 400 
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile
                405                 410                 415     
His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp
            420                 425                 430         
Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr
        435                 440                 445             
His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His
    450                 455                 460                 
Ser Gly Pro Thr Arg Met Ala Thr Ala Val Ala Arg Cys Ala Pro Asp
465                 470                 475                 480 
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg
                485                 490                 495     
Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala His
            500                 505                 510         
Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu
        515                 520                 525             
Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala Glu Ala
    530                 535                 540                 
Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr
545                 550                 555                 560 
Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro
                565                 570                 575     
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg
            580                 585                 590         
Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys
        595                 600                 605             
Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Thr Val
    610                 615                 620                 
Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly
625                 630                 635                 640 
Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
                645                 650                 655     
Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Gly Ala Val
            660                 665                 670         
Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser
        675                 680                 685             
Gln Glu Leu Gln
    690         


<210> 643
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Contact residues of AX132 FAb with PCSK9

<400> 643
Ser Gln Tyr Val Gly Ser Tyr Leu Asn
 1               5                  


<210> 644
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Contact residues of AX132 FAb with PCSK9

<400> 644
Tyr Val Gly Ser Tyr
 1               5  


<210> 645
<211> 80
<212> PRT
<213> Artificial Sequence

<220> 
<223> EGF_AB peptide

<400> 645
Asp Lys Val Cys Asn Met Ala Arg Asp Cys Arg Asp Trp Ser Asp Glu
 1               5                  10                  15      
Pro Ile Lys Glu Cys Gly Thr Asn Glu Cys Leu Asp Asn Asn Gly Gly
            20                  25                  30          
Cys Ser His Val Cys Asn Asp Leu Lys Ile Gly Tyr Glu Cys Leu Cys
        35                  40                  45              
Pro Asp Gly Phe Gln Leu Val Ala Gln Arg Arg Cys Glu Asp Ile Asp
    50                  55                  60                  
Glu Cys Gln Asp Pro Asp Thr Cys Ser Gln Leu Cys Val Asn Leu Glu
65                  70                  75                  80  


<210> 646
<211> 6065
<212> DNA
<213> Artificial Sequence

<220> 
<223> pMAB9-AX132 Antibody Expression Vector

<400> 646
gcgcaacgca attaatgtga gttagctcac tcattaggca ccccaggctt tacactttat 60
gcttccggct cgtatgttgt gtggaattgt gagcggataa caatttaccg gttctttaag 120
gaggaattaa aaaatgaaaa agtctttagt cctcaaagcc tccgtagccg ttgctaccct 180
cgttccgatg ctaagcttcg ctgaaatcgt gctgacccag tctccagcca ccctgtctct 240
gtctcccggg gaacgtgcca ccatcacctg ccgtgcctct cagtatgtcg gcagctacct 300
gaactggtat cagcagaagc caggtcaggc gccacgtctg ctgatctacg acgcctctaa 360
ccgtgccacc ggtatcccag cccgtttctc tggttctggt tctggcaccg acttcaccct 420
gaccatctct tctctggaac cagaagactt cgccgtgtac tactgccagg tatgggacag 480
ctctcctcct gtggtgttcg gtggtggtac caaagtggag atcaaacgta cggtggctgc 540
accatctgtc ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt 600
tgtgtgcctg ctgaataact tctatcccag agaggccaaa gtacagtgga aggtggataa 660
cgccctccaa tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac 720
ctacagcctc agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta 780
cgcctgcgaa gtcacccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg 840
agagtgttga taaggcgcgc cacaatttca cagtaaggag gtttaactta tgaaaaaatt 900
attattcgca attcctttag ttgttccttt ctattctcac tccgaagtgc aattgctgga 960
atctggtggt ggtctggtgc agccaggtgg ttctctgcgt ctgtcttgca aggcctctgg 1020
ttacaccttc tcttcttacg ggatgtactg ggtgcgtcag gcaccaggta agggtctgga 1080
atggatcggt tggatcgacc caggcagcgg tggcaccaag tacaacgaaa agttcaaggg 1140
taaggccacc atctccagag acaactctaa gaacaccctg tacttgcaga tgaactctct 1200
gcgtgccgag gacactgcag tgtactactg cgcccgtgaa cgttacggtt actacttcga 1260
ctactggggt cagggtacgc tggtgactgt ctcgagcgca agcaccaaag gcccatcggt 1320
attccccctg gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct 1380
ggtcaaggac tacttccccg agccggtgac ggtgtcgtgg aactcaggcg ctctgaccag 1440
cggcgtgcac accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt 1500
ggtgactgtg ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa 1560
gcccagcaac actaaggtgg acaagaaagt tgagcccaaa tcttgtgaca aaactcacac 1620
agcggccgct tatccatacg acgtaccaga ctacgcagga ggtcatcacc atcatcacca 1680
ttaatgaacc tgtgaagtga aaaatggcgc agattgtgcg acatgatcat tgggctgcaa 1740
aacaaaacgg cctcctgtca ggaagccgct tttatcgggt agcctcactg cccgctttcc 1800
agtcgggaaa cctgtcgtgc cagctgcatc agtgaatcgg ccaacgcgcg gggagaggcg 1860
gtttgcgtat tgggagccag ggtggttttt cttttcacca gtgagacggg caacagctga 1920
ttgcccttca ccgcctggcc ctgagagagt tgcagcaagc ggtccacgct ggtttgcccc 1980
agcaggcgaa aatcctgttt gatggtggtc agcggcggga tataacatga gctgtcctcg 2040
gtatcgtcgt atcccactac cgagatgtcc gcaccaacgc gcagcccgga ctcggtaatg 2100
gcacgcattg cgcccagcgc catctgatcg ttggcaacca gcatcgcagt gggaacgatg 2160
ccctcattca gcatttgcat ggtttgttga aaaccggaca tggcactcca gtcgccttcc 2220
cgttccgcta tcggctgaat ttgattgcga gtgagatatt tatgccagcc agccagacgc 2280
agacgcgccg agacagaact taatgggcca gctaacagcg cgatttgctg gtggcccaat 2340
gcgaccagat gctccacgcc cagtcgcgta ccgtcctcat gggagaaaat aatactgttg 2400
atgggtgtct ggtcagagac atcaagaaat aacgccggaa cattagtgca ggcagcttcc 2460
acagcaatag catcctggtc atccagcgga tagttaataa tcagcccact gacacgttgc 2520
gcgagaagat tgtgcaccgc cgctttacag gcttcgacgc cgcttcgttc taccatcgac 2580
acgaccacgc tggcacccag ttgatcggcg cgagatttaa tcgccgcgac aatttgcgac 2640
ggcgcgtgca gggccagact ggaggtggca acgccaatca gcaacgactg tttgcccgcc 2700
agttgttgtg ccacgcggtt aggaatgtaa ttcagctccg ccatcgccgc ttccactttt 2760
tcccgcgttt tcgcagaaac gtggctggcc tggttcacca cgcgggaaac ggtctgataa 2820
gagacaccgg catactctgc gacatcgtat aacgttactg gtttcacatt caccaccctg 2880
aattgactct cttccgggcg ctatcatgcc ataccgcgaa aggttttgcg ccattcgatg 2940
tcgacctcga ccaattcgcc ctatagtgag tcgtattacg cgcgctcact ggccgtcgtt 3000
ttacaacgtc gtgactggga aaaccctggc gttacccaac ttaatcgcct tgcagcacat 3060
ccccctttcg ccagctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 3120
ttgcgcagcc tgaatggcga atgggacgcg ccctgtagcg gcgcattaag cgcggcgggt 3180
gtggtggtta cgcgcagcgt gaccgctaca cttgccagcg ccctagcgcc cgctcctttc 3240
gctttcttcc cttcctttct cgccacgttc gccggctttc cccgtcaagc tctaaatcgg 3300
gggctccctt tagggttccg atttagtgct ttacggcacc tcgaccccaa aaaacttgat 3360
tagggtgatg gttcacgtag tgggccatcg ccctgataga cggtttttcg ccctttgacg 3420
ttggagtcca cgttctttaa tagtggactc ttgttccaaa ctggaacaac actcaaccct 3480
atctcggtct attcttttga tttataaggg attttgccga tttcggccta ttggttaaaa 3540
aatgagctga tttaacaaaa atttaacgcg aattttaaca aaatattaac gcttacaatt 3600
taggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttattt ttctaaatac 3660
attcaaatat gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa 3720
aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt tttgcggcat 3780
tttgccttcc tgtttttgct cacccagaaa cgctggtgaa agtaaaagat gctgaagatc 3840
agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag atccttgaga 3900
gttttcgccc cgaagaacgt tttccaatga tgagcacttt ttgatcagaa aaaaaggatc 3960
atatcgtcaa ttattacctc cacggggaga gcctgagcaa actggcctca ggcatttgag 4020
aagcacacgg tcacactgct tccggtagtc aataaaccgg taaaccagca atagacataa 4080
gcggctattt aacgaccctg ccctgaaccg acgaccgggt cgaatttgct ttcgaatttc 4140
tgccattcat ccgcttatta tcacttattc aggcgtagca accaggcgtt taagggcacc 4200
aataactgcc ttaaaaaaat tacgccccgc cctgccactc atcgcagtac tgttgtaatt 4260
cattaagcat tctgccgaca tggaagccat cacaaacggc atgatgaacc tgaatcgcca 4320
gcggcatcag caccttgtcg ccttgcgtat aatatttgcc catggtgaaa acgggggcga 4380
agaagttgtc catattggcc acgtttaaat caaaactggt gaaactcacc cagggattgg 4440
ctgagacgaa aaacatattc tcaataaacc ctttagggaa ataggccagg ttttcaccgt 4500
aacacgccac atcttgcgaa tatatgtgta gaaactgccg gaaatcgtcg tggtattcac 4560
tccagagcga tgaaaacgtt tcagtttgct catggaaaac ggtgtaacaa gggtgaacac 4620
tatcccatat caccagctca ccgtctttca ttgccatacg taattccgga tgagcattca 4680
tcaggcgggc aagaatgtga ataaaggccg gataaaactt gtgcttattt ttctttacgg 4740
tctttaaaaa ggccgtaata tccagctgaa cggtctggtt ataggtacat tgagcaactg 4800
actgaaatgc ctcaaaatgt tctttacgat gccattggga tatatcaacg gtggtatatc 4860
cagtgatttt tttctccatt ttagcttcct tagctcctga aaatctcgac aactcaaaaa 4920
atacgcccgg tagtgatctt atttcattat ggtgaaagtt ggaacctctt acgtgccgat 4980
caacgtctca ttttcgccaa aagttggccc agggcttccc ggtatcaaca gggacaccag 5040
gatttattta ttctgcgaag tgatcttccg tcacaggtat ttattcggtc gaaaaggatc 5100
taggtgaaga tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc 5160
cactgagcgt cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg 5220
cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg 5280
gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca 5340
aatactgttc ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg 5400
cctacatacc tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg 5460
tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga 5520
acggggggtt cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac 5580
ctacagcgtg agctatgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat 5640
ccggtaagcg gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc 5700
tggtatcttt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga 5760
tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc 5820
ctggcctttt gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg 5880
gataaccgta ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag 5940
cgcagcgagt cagtgagcga ggaagcggaa gagcgcccaa tacgcaaacc gcctctcccc 6000
gcgcgttggc cgattcatta atgcagctgg cacgacaggt ttcccgactg gaaagcgggc 6060
agtga                                                             6065



<210> 647
<211> 6065
<212> DNA
<213> Artificial Sequence

<220> 
<223> pMAB9-AX132 (complementary) sequence

<400> 647
tcactgcccg ctttccagtc gggaaacctg tcgtgccagc tgcattaatg aatcggccaa 60
cgcgcgggga gaggcggttt gcgtattggg cgctcttccg cttcctcgct cactgactcg 120
ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 180
ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag 240
gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg cccccctgac 300
gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 360
taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt 420
accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc 480
tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 540
cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caacccggta 600
agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggtat 660
gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac tagaagaaca 720
gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 780
tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt 840
acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct 900
cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc 960
acctagatcc ttttcgaccg aataaatacc tgtgacggaa gatcacttcg cagaataaat 1020
aaatcctggt gtccctgttg ataccgggaa gccctgggcc aacttttggc gaaaatgaga 1080
cgttgatcgg cacgtaagag gttccaactt tcaccataat gaaataagat cactaccggg 1140
cgtatttttt gagttgtcga gattttcagg agctaaggaa gctaaaatgg agaaaaaaat 1200
cactggatat accaccgttg atatatccca atggcatcgt aaagaacatt ttgaggcatt 1260
tcagtcagtt gctcaatgta cctataacca gaccgttcag ctggatatta cggccttttt 1320
aaagaccgta aagaaaaata agcacaagtt ttatccggcc tttattcaca ttcttgcccg 1380
cctgatgaat gctcatccgg aattacgtat ggcaatgaaa gacggtgagc tggtgatatg 1440
ggatagtgtt cacccttgtt acaccgtttt ccatgagcaa actgaaacgt tttcatcgct 1500
ctggagtgaa taccacgacg atttccggca gtttctacac atatattcgc aagatgtggc 1560
gtgttacggt gaaaacctgg cctatttccc taaagggttt attgagaata tgtttttcgt 1620
ctcagccaat ccctgggtga gtttcaccag ttttgattta aacgtggcca atatggacaa 1680
cttcttcgcc cccgttttca ccatgggcaa atattatacg caaggcgaca aggtgctgat 1740
gccgctggcg attcaggttc atcatgccgt ttgtgatggc ttccatgtcg gcagaatgct 1800
taatgaatta caacagtact gcgatgagtg gcagggcggg gcgtaatttt tttaaggcag 1860
ttattggtgc ccttaaacgc ctggttgcta cgcctgaata agtgataata agcggatgaa 1920
tggcagaaat tcgaaagcaa attcgacccg gtcgtcggtt cagggcaggg tcgttaaata 1980
gccgcttatg tctattgctg gtttaccggt ttattgacta ccggaagcag tgtgaccgtg 2040
tgcttctcaa atgcctgagg ccagtttgct caggctctcc ccgtggaggt aataattgac 2100
gatatgatcc tttttttctg atcaaaaagt gctcatcatt ggaaaacgtt cttcggggcg 2160
aaaactctca aggatcttac cgctgttgag atccagttcg atgtaaccca ctcgtgcacc 2220
caactgatct tcagcatctt ttactttcac cagcgtttct gggtgagcaa aaacaggaag 2280
gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa tgttgaatac tcatactctt 2340
cctttttcaa tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt 2400
tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc 2460
acctaaattg taagcgttaa tattttgtta aaattcgcgt taaatttttg ttaaatcagc 2520
tcatttttta accaataggc cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 2580
gagatagggt tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 2640
tccaacgtca aagggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 2700
ccctaatcaa gttttttggg gtcgaggtgc cgtaaagcac taaatcggaa ccctaaaggg 2760
agcccccgat ttagagcttg acggggaaag ccggcgaacg tggcgagaaa ggaagggaag 2820
aaagcgaaag gagcgggcgc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 2880
accacacccg ccgcgcttaa tgcgccgcta cagggcgcgt cccattcgcc attcaggctg 2940
cgcaactgtt gggaagggcg atcggtgcgg gcctcttcgc tattacgcca gctggcgaaa 3000
gggggatgtg ctgcaaggcg attaagttgg gtaacgccag ggttttccca gtcacgacgt 3060
tgtaaaacga cggccagtga gcgcgcgtaa tacgactcac tatagggcga attggtcgag 3120
gtcgacatcg aatggcgcaa aacctttcgc ggtatggcat gatagcgccc ggaagagagt 3180
caattcaggg tggtgaatgt gaaaccagta acgttatacg atgtcgcaga gtatgccggt 3240
gtctcttatc agaccgtttc ccgcgtggtg aaccaggcca gccacgtttc tgcgaaaacg 3300
cgggaaaaag tggaagcggc gatggcggag ctgaattaca ttcctaaccg cgtggcacaa 3360
caactggcgg gcaaacagtc gttgctgatt ggcgttgcca cctccagtct ggccctgcac 3420
gcgccgtcgc aaattgtcgc ggcgattaaa tctcgcgccg atcaactggg tgccagcgtg 3480
gtcgtgtcga tggtagaacg aagcggcgtc gaagcctgta aagcggcggt gcacaatctt 3540
ctcgcgcaac gtgtcagtgg gctgattatt aactatccgc tggatgacca ggatgctatt 3600
gctgtggaag ctgcctgcac taatgttccg gcgttatttc ttgatgtctc tgaccagaca 3660
cccatcaaca gtattatttt ctcccatgag gacggtacgc gactgggcgt ggagcatctg 3720
gtcgcattgg gccaccagca aatcgcgctg ttagctggcc cattaagttc tgtctcggcg 3780
cgtctgcgtc tggctggctg gcataaatat ctcactcgca atcaaattca gccgatagcg 3840
gaacgggaag gcgactggag tgccatgtcc ggttttcaac aaaccatgca aatgctgaat 3900
gagggcatcg ttcccactgc gatgctggtt gccaacgatc agatggcgct gggcgcaatg 3960
cgtgccatta ccgagtccgg gctgcgcgtt ggtgcggaca tctcggtagt gggatacgac 4020
gataccgagg acagctcatg ttatatcccg ccgctgacca ccatcaaaca ggattttcgc 4080
ctgctggggc aaaccagcgt ggaccgcttg ctgcaactct ctcagggcca ggcggtgaag 4140
ggcaatcagc tgttgcccgt ctcactggtg aaaagaaaaa ccaccctggc tcccaatacg 4200
caaaccgcct ctccccgcgc gttggccgat tcactgatgc agctggcacg acaggtttcc 4260
cgactggaaa gcgggcagtg aggctacccg ataaaagcgg cttcctgaca ggaggccgtt 4320
ttgttttgca gcccaatgat catgtcgcac aatctgcgcc atttttcact tcacaggttc 4380
attaatggtg atgatggtga tgacctcctg cgtagtctgg tacgtcgtat ggataagcgg 4440
ccgctgtgtg agttttgtca caagatttgg gctcaacttt cttgtccacc ttagtgttgc 4500
tgggcttgtg attcacgttg cagatgtagg tctgggtgcc caagctgctg gagggcacag 4560
tcaccacgct gctgagggag tagagtcctg aggactgtag gacagccggg aaggtgtgca 4620
cgccgctggt cagagcgcct gagttccacg acaccgtcac cggctcgggg aagtagtcct 4680
tgaccaggca gcccagggcc gctgtgcccc cagaggtgct cttggaggag ggtgccaggg 4740
ggaataccga tgggcctttg gtgcttgcgc tcgagacagt caccagcgta ccctgacccc 4800
agtagtcgaa gtagtaaccg taacgttcac gggcgcagta gtacactgca gtgtcctcgg 4860
cacgcagaga gttcatctgc aagtacaggg tgttcttaga gttgtctctg gagatggtgg 4920
ccttaccctt gaacttttcg ttgtacttgg tgccaccgct gcctgggtcg atccaaccga 4980
tccattccag acccttacct ggtgcctgac gcacccagta catcccgtaa gaagagaagg 5040
tgtaaccaga ggccttgcaa gacagacgca gagaaccacc tggctgcacc agaccaccac 5100
cagattccag caattgcact tcggagtgag aatagaaagg aacaactaaa ggaattgcga 5160
ataataattt tttcataagt taaacctcct tactgtgaaa ttgtggcgcg ccttatcaac 5220
actctcccct gttgaagctc tttgtgacgg gcgagctcag gccctgatgg gtgacttcgc 5280
aggcgtagac tttgtgtttc tcgtagtctg ctttgctcag cgtcagggtg ctgctgaggc 5340
tgtaggtgct gtccttgctg tcctgctctg tgacactctc ctgggagtta cccgattgga 5400
gggcgttatc caccttccac tgtactttgg cctctctggg atagaagtta ttcagcaggc 5460
acacaacaga ggcagttcca gatttcaact gctcatcaga tggcgggaag atgaagacag 5520
atggtgcagc caccgtacgt ttgatctcca ctttggtacc accaccgaac accacaggag 5580
gagagctgtc ccatacctgg cagtagtaca cggcgaagtc ttctggttcc agagaagaga 5640
tggtcagggt gaagtcggtg ccagaaccag aaccagagaa acgggctggg ataccggtgg 5700
cacggttaga ggcgtcgtag atcagcagac gtggcgcctg acctggcttc tgctgatacc 5760
agttcaggta gctgccgaca tactgagagg cacggcaggt gatggtggca cgttccccgg 5820
gagacagaga cagggtggct ggagactggg tcagcacgat ttcagcgaag cttagcatcg 5880
gaacgagggt agcaacggct acggaggctt tgaggactaa agactttttc attttttaat 5940
tcctccttaa agaaccggta aattgttatc cgctcacaat tccacacaac atacgagccg 6000
gaagcataaa gtgtaaagcc tggggtgcct aatgagtgag ctaactcaca ttaattgcgt 6060
tgcgc                                                             6065


